New! View global litigation for patent families

US20070185091A1 - Bicyclic Heterocycles, Pharmaceutical Compositions Containing These Compounds, Their Use and Processes for Preparing Them - Google Patents

Bicyclic Heterocycles, Pharmaceutical Compositions Containing These Compounds, Their Use and Processes for Preparing Them Download PDF

Info

Publication number
US20070185091A1
US20070185091A1 US11734350 US73435007A US2007185091A1 US 20070185091 A1 US20070185091 A1 US 20070185091A1 US 11734350 US11734350 US 11734350 US 73435007 A US73435007 A US 73435007A US 2007185091 A1 US2007185091 A1 US 2007185091A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
group
amino
yl
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11734350
Inventor
Frank Himmelsbach
Elke Langkopf
Thomas Metz
Flavio Solca
Birgit Jung
Anke Baum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to bicyclic heterocycles of general formula
Figure US20070185091A1-20070809-C00001
 wherein
    • Ra to Rc, A to E and X are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.

Description

  • [0001]
    The present invention relates to bicyclic heterocycles of general formula
    Figure US20070185091A1-20070809-C00002
    the tautomers, the stereoisomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract, and the preparation thereof.
  • [0002]
    In the above general formula I:
  • [0000]
    Ra denotes a hydrogen atom or a C1-4-alkyl group,
  • [0000]
    Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R1 to R3, whilst
  • [0000]
      • R1 and R2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom,
      • a C1-4-alkyl, hydroxy, C1-4-alkoxy, C3-6-cycloalkyl, C4-6-cycloalkoxy, C2-5-alkenyl or C2-5-alkynyl group,
      • an aryl, aryloxy, arylmethyl or arylmethoxy group,
      • a C3-5-alkenyloxy or C3-5-alkynyloxy group, whilst the unsaturated moiety may not be linked to the oxygen atom,
      • a C1-4-alkylsulfenyl, C1-4-alkylsulfinyl, C1-4-alkylsulfonyl, C1-4-alkylsulfonyloxy, trifluoromethylsulfenyl, trifluoromethylsulfinyl or trifluoromethylsulfonyl group,
      • a methyl or methoxy group substituted by 1 to 3 fluorine atoms,
      • an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms,
      • a cyano or nitro group or an amino group optionally substituted by one or two C1-4-alkyl groups, wherein the substitutents may be identical or different, or
      • R1 together with R2, if they are bound to adjacent carbon atoms, denote a —CH═CH—CH═CH, —CH═CH—NH or —CH═N—NH group and
      • R3 denotes a hydrogen, fluorine, chlorine or bromine atom,
      • a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group,
        X denotes a methine group substituted by a cyano group or a nitrogen atom,
        A denotes an imino group optionally substituted by a C1-4-alkyl group,
        B denotes a carbonyl or sulfonyl group,
        C denotes a 1,3-allenylene, 1,1- or 1,2-vinylene group which may be substituted in each case by one or two methyl groups or by a trifluoromethyl group,
        an ethynylene group or
        a 1,3-butadien-1,4-ylene group optionally substituted by 1 to 4 methyl groups or by a trifluoromethyl group,
        D denotes an alkylene, —CO-alkylene or —SO2-alkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, whilst the linking of the —CO-alkylene or —SO2-alkylene group to the adjacent group C in each case must take place via the carbonyl or sulfonyl group,
        a —CO—O-alkylene, —CO—NR4-alkylene or —SO2—NR4-alkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms, whilst the linking to the adjacent group C in each case must take place via the carbonyl or sulfonyl group, wherein
      • R4 denotes a hydrogen atom or a C1-4-alkyl group,
        or, if D is bound to a carbon atom of the group E, it may also denote a bond
        or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulfonyl group,
        E denotes an amino, C1-4-alkylamino or di-(C1-4-alkyl)-amino group wherein the alkyl moieties may be identical or different,
        a C2-4-alkylamino group wherein the alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, whilst
      • R5 denotes a hydroxy, C1-4-alkoxy, amino, C1-4-alkylamino or di-(C1-4-alkyl)-amino group,
      • a 4- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups or
      • a 6- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups wherein in each case a methylene group in position 4 is replaced by an oxygen or sulfur atom, by a sulfinyl, sulfonyl, imino or N—(C1-4-alkyl)-imino group,
        an N—(C1-4-alkyl)-N—(C2-4-alkyl)-amino group wherein the C2-4-alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, whilst R5 is as hereinbefore defined,
        a di-(C2-4-alkyl)-amino group wherein the two C2-4-alkyl moieties are substituted in each case in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, whilst the substitutents may be identical or different and R5 is as hereinbefore defined,
        a C3-7-cycloalkylamino or C3-7-cycloalkyl-C1-3-alkylamino group wherein in each case the nitrogen atom may be substituted by a further C1-4-alkyl group,
        an amino or C1-4-alkylamino group wherein in each case the nitrogen atom is substituted by a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, 1-(tetrahydrofuran-3-yl)piperidin-4-yl, 1-(tetrahydropyran-3-yl)piperidin-4-yl, 1-(tetrahydropyran-4-yl)piperidin-4-yl, 3-pyrrolidinyl, 3-piperidinyl, 4-piperidinyl, 3-hexahydro-azepinyl or 4-hexahydro-azepinyl group optionally substituted by 1 to 3 C1-4-alkyl groups,
        a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 C1-2-alkyl groups, which may be substituted by the group R5 either at a cyclic carbon atom or at one of the alkyl groups, whilst R5 is as hereinbefore defined,
        a piperidino group substituted by a tetrahydrofuranyl, tetrahydropyranyl or tetrahydrofuranylmethyl group,
        a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 C1-2-alkyl groups wherein a methylene group in each case is replaced in the 4 position by an oxygen or sulfur atom, by an imino group substituted by the group R6, or by a sulfinyl or sulfonyl group, whilst
      • R6 denotes a hydrogen atom, a C1-4-alkyl, 2-methoxyethyl, 3-methoxypropyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, formyl, C1-4-alkylcarbonyl, C1-4-alkylsulfonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group,
        an imidazolyl group optionally substituted by 1 to 3 methyl groups,
        a C5-7-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulfur atom, by an imino group substituted by the group R6, by a sulfinyl or sulfonyl group, whilst R6 is as hereinbefore defined,
        or D together with E denotes a hydrogen, fluorine or chlorine atom,
        a C1-4-alkyl group optionally substituted by 1 to 5 fluorine atoms,
        a C3-6-cycloalkyl group,
        an aryl, heteroaryl, C1-4-alkylcarbonyl or arylcarbonyl group,
        a carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group or
        a carbonyl which is substituted by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group may be replaced in the 4 position by an oxygen or sulfur atom, by an imino group substituted by the group R6, by a sulfinyl or sulfonyl group, whilst R6 is as hereinbefore defined, and
        Rc denotes a C4-7-cycloalkoxy or C3-7-cycloalkyl-C1-6-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C1-3-alkyl, hydroxy, C1-4-alkoxy, amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, pyrrolidino, piperidino, morpholino, piperazino, N—(C1-2-alkyl)-piperazino, hydroxy-C1-2-alkyl, C1-4-alkoxy-C1-2-alkyl, amino-C1-2-alkyl, C1-4-alkylamino-C1-2-alkyl, di-(C1-4-alkyl)-amino-C1-2-alkyl, pyrrolidino-C1-2-alkyl, piperidino-C1-2-alkyl, morpholino-C1-2-alkyl, piperazino-C1-2-alkyl or N—(C1-2-alkyl)-piperazino-C1-2-alkyl group, whilst the abovementioned monosubstituted cycloalkyl moieties may additionally be substituted by a C1-3-alkyl group,
        a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuranylmethoxy group,
        an C2-4-alkoxy group substituted in β-, γ-, or δ-position with regard to the oxygen atom by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,
        a 3-pyrrolidinyloxy, 2-pyrrolidinyl-C1-4-alkyloxy, 3-pyrrolidinyl-C1-4-alkyloxy, 3-piperidinyloxy, 4-piperidinyloxy, 2-piperidinyl-C1-4-alkyloxy, 3-piperidinyl-C1-4-alkyloxy, 4-piperidinyl-C1-4-alkyloxy, 3-hexahydro-azepinyloxy, 4-hexahydro-azepinyloxy, 2-hexahydro-azepinyl-C1-4-alkyloxy, 3-He-xahydro-azepinyl-C1-4-alkyloxy or 4-hexahydro-azepinyl-C1-4-alkyloxy group wherein in each case the cyclic nitrogen atom is substituted by the group R6, where R6 is as hereinbefore defined,
        particularly those compounds of general formula I wherein Ra, Rb, A to C and X are as hereinbefore defined,
        E denotes an amino, C1-4-alkylamino or di-(C1-4-alkyl)-amino group wherein the alkyl moieties may be identical or different,
        a C2-4-alkylamino group wherein the alkyl moiety is substituted from position 2 by the group R5, whilst
      • R5 denotes a hydroxy, C1-4-alkoxy, amino, C1-4-alkylamino or di-(C1-4-alkyl)-amino group,
      • a 4- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups or
      • a 6- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups wherein in each case a methylene group in position 4 is replaced by an oxygen or sulfur atom, by a sulfinyl, sulfonyl, imino or N—(C1-4-alkyl)-imino group,
        an N—(C1-4-alkyl)-N—(C2-4-alkyl)-amino group wherein the C2-4-alkyl moiety is substituted from position 2 onwards by the group R5, where R5 is as hereinbefore defined,
        a di-(C2-4-alkyl)-amino group wherein the two C2-4-alkyl moieties are substituted in each case from position 2 onwards by the group R5, whilst the substitutents may be identical or different and R5 is as hereinbefore defined,
        a C3-7-cycloalkylamino or C3-7-cycloalkyl-C1-3-alkylamino group wherein in each case the nitrogen atom may be substituted by a further C1-4-alkyl group,
        an amino or C1-4-alkylamino group wherein in each case the nitrogen atom is substituted by a 3-pyrrolidinyl, 3-piperidinyl, 4-piperidinyl, 3-hexahydro-azepinyl or 4-hexahydro-azepinyl group optionally substituted by 1 to 3 C1-4-alkyl groups,
        a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 C1-2-alkyl groups, which may be substituted by the group R5 either at a cyclic carbon atom or at one of the alkyl groups, whilst R5 is as hereinbefore defined, or
        a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 C1-2-alkyl groups wherein a methylene group in each case is replaced in the 4 position by an oxygen or sulfur atom, by an imino group substituted by the group R6, or by a sulfinyl or sulfonyl group, whilst
      • R6 denotes a hydrogen atom, a C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, formyl, C1-4-alkylcarbonyl, C1-4-alkylsulfonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group,
        an imidazolyl group optionally substituted by 1 to 3 methyl groups,
        a C5-7-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulfur atom, by an imino group substituted by the group R6, by a sulfinyl or sulfonyl group, whilst R6 is as hereinbefore defined,
        or D together with E denotes a hydrogen, fluorine or chlorine atom,
        a C1-4-alkyl group optionally substituted by 1 to 5 fluorine atoms,
        a C3-6-cycloalkyl group,
        an aryl, heteroaryl, C1-4-alkylcarbonyl or arylcarbonyl group,
        a carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group or
        a carbonyl which is substituted by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups a methylene group may in each case be replaced in the 4 position by an oxygen or sulfur atom, by an imino group substituted by the group R6, by a sulfinyl or sulfonyl group, whilst R6 is as hereinbefore defined, and
        Rc denotes a C4-7-cycloalkoxy or C3-7-cycloalkyl-C1-6-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C1-3-alkyl, hydroxy, C1-4-alkoxy, amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, pyrrolidino, piperidino, morpholino, piperazino, N—(C1-2-alkyl)-piperazino, hydroxy-C1-2-alkyl, C1-4-alkoxy-C1-2-alkyl, amino-C1-2-alkyl, C1-4-alkylamino-C1-2-alkyl, di-(C1-4-alkyl)-amino-C1-2-alkyl, pyrrolidino-C1-2-alkyl, piperidino-C1-2-alkyl, morpholino-C1-2-alkyl, piperazino-C1-2-alkyl or N—(C1-2-alkyl)-piperazino-C1-2-alkyl group, whilst the abovementioned monosubstituted cycloalkyl moieties may additionally be substituted by a C1-3-alkyl group, or
        a 3-pyrrolidinyloxy, 2-pyrrolidinyl-C1-4-alkyloxy, 3-pyrrolidinyl-C1-4-alkyloxy, 3-piperidinyloxy, 4-piperidinyloxy, 2-piperidinyl-C1-4-alkyloxy, 3-piperidinyl-C1-4-alkyloxy, 4-piperidinyl-C1-4-alkyloxy, 3-hexahydro-azepinyloxy, 4-hexahydro-azepinyloxy, 2-hexahydro-azepinyl-C1-4-alkyloxy, 3-hexahydro-azepinyl-C1-4-alkyloxy or 4-hexahydro-azepinyl-C1-4-alkyloxy group wherein in each case the cyclic nitrogen atom is substituted by the group R6, where R6 is as hereinbefore defined.
  • [0023]
    By the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which in each case may be monosubstituted by R7, mono-, di- or trisubstituted by R8 or monosubstituted by R7 and additionally mono- or disubstituted by R8, wherein the substitutents may be identical or different and
      • R7 denotes a cyano, carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl, di-(C1-4-alkyl)-aminocarbonyl, C1-4-alkylsulfenyl, C1-4-alkylsulfinyl, C1-4-alkylsulfonyl, hydroxy, C1-4-alkylsulfonyloxy, trifluoromethyloxy, nitro, amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, C1-4-alkylcarbonylamino, N—(C1-4-alkyl)-C1-4-alkylcarbonylamino, C1-4-alkylsulfonylamino, N—(C1-4-alkyl)-C1-4-alkylsulfonylamino, aminosulfonyl, C1-4-alkylaminosulfonyl or di-(C1-4-alkyl)-aminosulfonyl group or a carbonyl group which is substituted by a 5- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulfur atom, by a sulfinyl, sulfonyl, imino or N—(C1-4-alkyl)-imino group, and
      • R8 denotes a fluorine, chlorine, bromine or iodine atom, a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group or
      • two groups R8, if they are bound to adjacent carbon atoms, together denote a C3-5-alkylene, methylenedioxy or 1,3-butadien-1,4-ylene group.
  • [0027]
    The heteroaryl groups mentioned in the definition of the abovementioned groups also include a 5-membered heteroaromatic group which contains an imino group, an oxygen or sulfur atom or an imino group, an oxygen or sulfur atom and one or two nitrogen atoms, or
  • [0028]
    a 6-membered heteroaromatic group which contains one, two or three nitrogen atoms, whilst the abovementioned 5-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups and the abovementioned 6-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups or by a fluorine, chlorine, bromine or iodine atom or by a trifluoromethyl, hydroxy, methoxy or ethoxy group.
  • [0029]
    Preferred compounds of the above general formula I are those wherein
  • [0000]
    Ra denotes a hydrogen atom,
  • [0000]
    Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R1 to R3, whilst
  • [0000]
      • R1 and R2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom,
      • a C1-4-alkyl, hydroxy, C1-4-alkoxy, C3-6-cycloalkyl, C4-6-cycloalkoxy, C2-5-alkenyl or C2-5-alkynyl group,
      • an aryl, aryloxy, arylmethyl or arylmethoxy group,
      • a methyl or methoxy group substituted by 1 to 3 fluorine atoms, a cyano or nitro group and
      • R3 denotes a hydrogen, fluorine, chlorine or bromine atom,
      • a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group,
        X denotes a methine group substituted by a cyano group or a nitrogen atom,
        A denotes an imino group,
        B denotes a carbonyl or sulfonyl group,
        C denotes a 1,3-allenylene, 1,1- or 1,2-vinylene group,
        an ethynylene or 1,3-butadien-1,4-ylene group,
        D denotes an alkylene, —CO-alkylene or —SO2-alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, whilst the linking of the —CO-alkylene or —SO2-alkylene group to the adjacent group C in each case must take place via the carbonyl or sulfonyl group,
        a —CO—O-alkylene, —CO—NR4-alkylene or —SO2—NR4-alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms, whilst the linking to the adjacent group C in each case must take place via the carbonyl or sulfonyl group, wherein
      • R4 denotes a hydrogen atom or a C1-4-alkyl group,
        or, if D is bound to a carbon atom of the group E, it may also denote a bond,
        or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulfonyl group,
        E denotes a di-(C1-4-alkyl)-amino group wherein the alkyl moieties may be identical or different,
        an N—(C1-4-alkyl)-N—(C2-4-alkyl)-amino group wherein the C2-4-alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, where
      • R5 denotes a hydroxy, C1-4-alkoxy or di-(C1-4-alkyl)-amino group,
      • a 4- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups or
      • a 6- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups wherein in each case a methylene group in position 4 is replaced by an oxygen or sulfur atom, or by a sulfinyl, sulfonyl or N—(C1-4-alkyl)-imino group,
        a di-(C2-4-alkyl)-amino group wherein the two C2-4-alkyl moieties in each case are substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, wherein the substitutents may be identical or different and R5 is as hereinbefore defined,
        a C3-7-cycloalkylamino or C3-7-cycloalkyl-C1-3-alkylamino group wherein in each case the nitrogen atom is substituted by a further C1-4-alkyl group,
        a C1-4-alkylamino group wherein the nitrogen atom is substituted by a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, 1-(tetrahydrofuran-3-yl)piperidin-4-yl, 1-(tetrahydropyran-3-yl)piperidin-4-yl, 1-(tetrahydropyran-4-yl)piperidin-4-yl, N—(C1-2-alkyl)-3-pyrrolidinyl, N—(C1-2-alkyl)-3-piperidinyl, N—(C1-2-alkyl)-4-piperidinyl, N—(C1-2-alkyl)-3-hexahydro-azepinyl or N—(C1-2-alkyl)-4-hexahydro-azepinyl group,
        an 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups, which may be substituted either at a cyclic carbon atom or at one of the methyl groups by the group R5, where R5 is as hereinbefore defined,
        a piperidino group substituted by a tetrahydrofuranyl, tetrahydropyranyl or tetrahydrofuranylmethyl group,
        a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups wherein in each case a methylene group is replaced in the 4 position by an oxygen or sulfur atom, by an imino group substituted by the group R6, by a sulfinyl or sulfonyl group, whilst
      • R6 denotes a C1-4-alkyl, 2-methoxyethyl, 3-methoxypropyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, formyl, C1-4-alkylcarbonyl, C1-4-alkylsulfonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group,
        a C5-7-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulfur atom, by an imino group substituted by the group R6, or by a sulfinyl or sulfonyl group, where R6 is as hereinbefore defined,
        or D together with E denotes a hydrogen, fluorine or chlorine atom,
        a C1-4-alkyl group optionally substituted by 1 to 5 fluorine atoms,
        a C3-6-cycloalkyl group,
        an aryl, C1-4-alkylcarbonyl or arylcarbonyl group,
        a carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group or
        a carbonyl group which is substituted by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulfur atom, by an imino group substituted by the group R6, or by a sulfinyl or sulfonyl group, where R6 is as hereinbefore defined, and
        Rc denotes a C4-7-cycloalkoxy or C3-7-cycloalkyl-C1-6-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C1-3-alkyl, hydroxy, C1-4-alkoxy, di-(C1-4-alkyl)-amino, pyrrolidino, piperidino, morpholino, N—(C1-2-alkyl)-piperazino, hydroxy-C1-2-alkyl, C1-4-alkoxy-C1-2-alkyl, di-(C1-4-alkyl)-amino-C1-2-alkyl, pyrrolidino-C1-2-alkyl, piperidino-C1-2-alkyl, morpholino-C1-2-alkyl or N—(C1-2-alkyl)-piperazino-C1-2-alkyl group, whilst the abovementioned monosubstituted cycloalkyl moieties may additionally be substituted by a C1-3-alkyl group,
        a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuranylmethoxy group,
        an C2-4-alkoxy group substituted in β-, γ-, or δ-position with regard to the oxygen atom by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,
        a 3-pyrrolidinyloxy, 2-pyrrolidinyl-C1-4-alkyloxy, 3-pyrrolidinyl-C1-4-alkyloxy, 3-piperidinyloxy, 4-piperidinyloxy, 2-piperidinyl-C1-4-alkyloxy, 3-piperidinyl-C1-4-alkyloxy, 4-piperidinyl-C1-4-alkyloxy, 3-hexahydro-azepinyloxy, 4-hexahydro-azepinyloxy, 2-hexahydro-azepinyl-C1-4-alkyloxy, 3-hexahydro-azepinyl-C1-4-alkyloxy or 4-hexahydro-azepinyl-C1-4-alkyloxy group wherein in each case the cyclic nitrogen atom is substituted by the group R6, where R6 is as hereinbefore defined, whilst by the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which may in each case be monosubstituted by R7, mono-, di- or trisubstituted by R8 or monosubstituted by R7 and additionally mono- or disubstituted by R8, wherein the substitutents may be identical or different and
      • R7 denotes a cyano, carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl, di-(C1-4-alkyl)-aminocarbonyl, C1-4-alkylsulfenyl, C1-4-alkylsulfinyl, C1-4-alkylsulfonyl, hydroxy, C1-4-alkylsulfonyloxy, trifluoromethyloxy, nitro, amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, C1-4-alkylcarbonylamino, N—(C1-4-alkyl)-C1-4-alkylcarbonylamino, C1-4-alkylsulfonylamino, N—(C1-4-alkyl)-C1-4-alkylsulfonylamino, aminosulfonyl, C1-4-alkylaminosulfonyl or di-(C1-4-alkyl)-aminosulfonyl group or a carbonyl group which is substituted by a 5- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group may be replaced in the 4 position by an oxygen or sulfur atom, by a sulfinyl, sulfonyl, imino or N—(C1-4-alkyl)-imino group, and
      • R8 denotes a fluorine, chlorine, bromine or iodine atom, a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group or
      • two groups R8, if they are bound to adjacent carbon atoms, together denote a C3-5-alkylene, methylenedioxy or 1,3-butadien-1,4-ylene group,
        the tautomers, stereoisomers and salts thereof.
  • [0044]
    Particularly preferred compounds of the above general formula I are those wherein
  • [0000]
    Ra denotes a hydrogen atom,
  • [0000]
    Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R1 and R2, where
  • [0000]
      • R1 and R2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine or bromine atom,
      • a methyl, trifluoromethyl or methoxy group,
        X denotes a nitrogen atom,
        A denotes an imino group,
        B denotes a carbonyl group,
        C denotes a 1,2-vinylene group,
        an ethynylene or 1,3-butadien-1,4-ylene group,
        D denotes a C1-4-alkylene group,
        or, if D is bound to a carbon atom of the group E, it may also denote a bond,
        or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl group,
        E denotes a di-(C1-4-alkyl)-amino group wherein the alkyl moieties may be identical or different,
        an N—(C1-4-alkyl)-N—(C2-4-alkyl)-amino group wherein the C2-4-alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, whilst
      • R5 denotes a hydroxy, C1-3-alkoxy or di-(C1-3-alkyl)-amino group,
      • a pyrrolidino, piperidino or morpholino group,
        a di-(C2-4-alkyl)-amino group wherein the two C2-4-alkyl moieties in each case are substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, wherein the substitutents may be identical or different and R5 is as hereinbefore defined,
        an C1-4-alkylamino group substituted at the nitrogen atom by a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, 1-(C1-2-alkyl)-pyrrolidin-3-yl, 1-(C1-2-alkyl)-piperidin-3-yl, 1-(C1-2-alkyl)-piperidin-4-yl, 1-(tetrahydrofuran-3-yl)piperidin-4-yl, 1-(tetrahydropyran-3-yl)piperidin-4-yl or 1-(tetrahydropyran-4-yl)piperidin-4-yl group,
        a C3-5-cycloalkylamino or C3-5-cycloalkyl-C1-3-alkylamino group wherein in each case the nitrogen atom is substituted by a further C1-3-alkyl group,
        a 5- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups which may be substituted either at a cyclic carbon atom or at one or the methyl groups by the group R5, where R5 is as hereinbefore defined, or
        a piperidino group substituted by a tetrahydrofuranyl, tetrahydropyranyl or tetrahydrofuranylmethyl group,
        a piperidino group optionally substituted by 1 or 2 methyl groups wherein the methylene group is replaced in the 4 position by an oxygen or sulfur atom, by sulfinyl or sulfonyl group or by an imino group substituted by the group R6, whilst
      • R6 denotes a C1-3-alkyl, 2-methoxyethyl, 3-methoxypropyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-3-alkyl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, C1-3-alkylcarbonyl, C1-3-alkylsulfonyl, aminocarbonyl, C1-3-alkylaminocarbonyl or di-(C1-3-alkyl)-aminocarbonyl group,
        or D together with E denotes a hydrogen atom,
        a C1-3-alkyl group,
        an aryl or C1-4-alkylcarbonyl group or
        a C1-4-alkoxycarbonyl group,
        Rc denotes a C4-7-cycloalkoxy or C3-7-cycloalkyl-C1-4-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C1-3-alkyl or C1-3-alkoxy group,
        a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuranylmethoxy group,
        an C2-4-alkoxy group substituted in β-, γ-, or δ-position with regard to the oxygen atom by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,
        a 3-pyrrolidinyloxy, 2-pyrrolidinyl-C1-3-alkyloxy, 3-pyrrolidinyl-C1-3-alkyloxy, 3-piperidinyloxy, 4-piperidinyloxy, 2-piperidinyl-C1-3-alkyloxy, 3-piperidinyl-C1-3-alkyloxy, 4-piperidinyl-C1-3-alkyloxy, 3-hexahydro-azepinyloxy, 4-hexahydro-azepinyloxy, 2-hexahydro-azepinyl-C1-3-alkyloxy, 3-hexahydro-azepinyl-C1-3-alkyloxy or 4-hexahydro-azepinyl-C1-3-alkyloxy group wherein in each case the cyclic nitrogen atom is substituted by a methyl or ethyl group, whilst
        by the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which may be mono-, di- or trisubstituted by R8, wherein the substitutents may be identical or different and
      • R8 denotes a fluorine, chlorine, bromine or iodine atom, a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group,
        the tautomers, stereoisomers and salts thereof.
  • [0051]
    Most particularly preferred compounds of the above general formula I are those wherein
  • [0000]
    Ra denotes a hydrogen atom,
  • [0000]
    Rb denotes a phenyl, benzyl or 1-phenylethyl group, whilst the phenyl nucleus is substituted in each case by the radicals R1 and R2, whilst
  • [0000]
      • R1 and R2, which may be identical or different, each denotes a hydrogen, fluorine, chlorine or bromine atom,
        X denotes a nitrogen atom,
        A denotes an imino group,
        B denotes a carbonyl group,
        C denotes a 1,2-vinylene, ethinylene or 1,3-butadien-1,4-ylene group,
        D denotes an C1-3-alkylene group,
        E denotes a Di-(C1-4-alkyl)-amino group, wherein the alkyl moieties may be identical or different,
        a methylamino or ethylamino group each substituted at the nitrogen atom by a 2-methoxyethyl, 1-methoxy-2-propyl, 2-methoxypropyl, 3-methoxypropyl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl, tetrahydrofuran-2-ylmethyl, 1-methylpiperidin-4-yl, 1-ethylpiperidin-4-yl, 1-(tetrahydrofuran-3-yl)piperidin-4-yl, cyclopropyl or cyclopropylmethyl group,
        a Bis-(2-methoxyethyl)amino group,
        a pyrrolidino, piperidino or morpholino group each optionally substituted by one or two methyl groups,
        a piperazino group substituted in 4-position by a methyl, ethyl, cyclopropyl, cyclopropylmethyl, 2-methoxyethyl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl or tetrahydrofuran-2-ylmethyl group,
        a thiomorpholino, S-oxidothiomorpholino or S,S-dioxidothiomorpholino group,
        a 2-(methoxymethyl)pyrrolidino, 2-(ethoxymethyl)pyrrolidino, 4-hydroxypiperidino, 4-methoxypiperidino, 4-ethoxypiperidino, 4-(tetrahydrofuran-3-yl)piperidino or 4-morpholinopiperidino group
        or D together with E denote a hydrogen atom, a methyl, phenyl, methoxycarbonyl or ethoxycarbonyl group and
        Rc denotes a cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy or cyclohexylmethoxy group,
        a cyclobutyloxy, cyclopentyloxy or cyclohexyloxy group,
        a tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuran-2-ylmethoxy group,
        a straight chained C2-4-alkoxy group terminally substituted by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,
        a 1-methylpiperidin-4-yloxy or 1-ethylpiperidin-4-yloxy group,
        a (1-methylpiperidin-4-yl)-C1-3-alkyloxy or (1-ethylpiperidin-4-yl)-C1-3-alkyloxy group,
        especially those compounds wherein
        Ra denotes a hydrogen atom,
        Rb denotes a 1-phenylethyl group or a phenyl group wherein the phenyl nucleus is substituted by the radicals R1 and R2, whilst
      • R1 and R2, which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom,
        X denotes a nitrogen atom,
        A denotes an imino group,
        B denotes a carbonyl group,
        C denotes a 1,2-vinylene, ethinylene or 1,3-butadien-1,4-ylene group,
        D denotes a methylene group,
        E denotes a dimethylamino, diethylamino, bis(2-methoxyethyl)amino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, N-methyl-N-cyclopropyl-amino, N-methyl-N-cyclopropylmethyl-amino, N-methyl-N-(1-methoxy-2-propyl)amino, N-methyl-N-(2-methoxypropyl)amino, N-methyl-N-(3-methoxypropyl)amino-, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino or N-methyl-N-(1-methylpiperidin-4-yl)amino group,
        a pyrrolidino, piperidino or morpholino group each optionally substituted by one or two methyl groups,
        a piperazino group substituted in 4-position by a methyl, ethyl, cyclopropylmethyl or 2-methoxyethyl group,
        a S-oxidothiomorpholino group,
        a 2-(methoxymethyl)pyrrolidino, 4-hydroxypiperidino or 4-methoxypiperidino group
        or D together with E denote a hydrogen atom, a methyl, phenyl or ethoxycarbonyl group, and
        Rc denotes a cyclopropylmethoxy, cyclobutyloxy or cyclopentyloxy group,
        a tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuran-2-ylmethoxy group,
        a straight chained C2-4-alkoxy group terminally substituted by an azetidin-1-yl or 4-methyl-homopiperazino group,
        a 1-methylpiperidin-4-yloxy group or
        a (1-methylpiperidin-4-yl)-C1-3-alkyloxy group,
        the tautomers, stereoisomers and salts thereof.
  • [0054]
    The following particularly valuable compounds of general formula I may be mentioned by way of example:
    • (a) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline,
    • (b) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline and
    • (c) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
      as well as the salts thereof.
  • [0058]
    The compounds of general formula I may be prepared, for example, by the following processes:
    a) reacting a compound of general formula
    Figure US20070185091A1-20070809-C00003
    wherein
    Ra to Rc, A and X are as hereinbefore defined, with a compound of general formula
    Z1-B-C-D-E  (III)
    wherein
    B to E are as hereinbefore defined and
    Z1 denotes a leaving group such as a halogen atom, e.g., a chlorine or bromine atom, or a hydroxy group.
  • [0059]
    The reaction is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/-tetrahydrofuran or dioxane optionally in the presence of an inorganic or organic base and optionally in the presence of a dehydrating agent, expediently at temperatures between −50° C. and 150° C., preferably at temperatures between −20° C. and 80° C.
  • [0060]
    With a compound of general formula III wherein Z1 denotes a leaving group, the reaction is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane conveniently in the presence of a tertiary organic base such as triethylamine, pyridine or 2-dimethylaminopyridine, in the presence of N-ethyl-diisopropylamine (Hünig base), whilst these organic bases may simultaneously also act as solvent, or in the presence of an inorganic base such as sodium carbonate, potassium carbonate or sodium hydroxide solution expediently at temperatures between −50° C. and 150° C., preferably at temperatures between −20° C. and 80° C.
  • [0061]
    With a compound of general formula III wherein Z1 denotes a hydroxy group, the reaction is preferably carried out in the presence of a dehydrating agent, e.g., in the presence of isobutyl chloroformate, thionyl chloride, trimethyl chlorosilane, phosphorus trichloride, phosphorus pentoxide, hexamethyldisilazane, N,N′-dicyclohexylcarbodiimide, N,N′-dicyclohexylcarbodiimide/N-hydroxysuccinimide or 1-hydroxybenzotriazole and optionally also in the presence of 4-dimethylamino-pyridine, N,N′-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, expediently in a solvent such as methylene chloride, tetrahydrofuran, dioxane, toluene, chlorobenzene, dimethylsulfoxide, ethylene glycol monomethylether, ethylene glycol, diethylether or sulfolane and optionally in the presence of a reaction accelerator such as 4-dimethylaminopyridine at temperatures between −50° C. and 150° C., but preferably at temperatures between −20° C. and 80° C.
  • [0000]
    b) In order to prepare compounds of general formula I wherein the group E is linked to the group D via a nitrogen atom:
  • [0062]
    reacting a compound of general formula
    Figure US20070185091A1-20070809-C00004
    wherein
    Ra to Rc, A to D and X are as hereinbefore defined and Z2
    denotes a leaving group such as a halogen atom, a substituted hydroxy or sulfonyloxy group such as a chlorine or bromine atom, a methanesulfonyloxy or p-toluenesulfonyloxy group, with a compound of general formula
    H-E′  (V)
    wherein
    E′ denotes one of the groups mentioned for E hereinbefore, which is linked to the group D via a nitrogen atom.
  • [0063]
    The reaction is expediently carried out in a solvent such as isopropanol, butanol, tetrahydrofuran, dioxane, toluene, chlorobenzene, dimethylformamide, dimethylsulfoxide, methylene chloride, ethylene glycol monomethylether, ethylene glycol diethylether or sulfolane, optionally in the presence of an inorganic or tertiary organic base, e.g., sodium carbonate or potassium hydroxide, a tertiary organic base, e.g., triethylamine, or in the presence of N-ethyl-diisopropylamine (Hünig base), whilst these organic bases may simultaneously also serve as solvent, and optionally in the presence of a reaction accelerator such as an alkali metal halide at temperatures between −20° C. and 150° C., but preferably at temperatures between −10° C. and 100° C. The reaction may, however, also be carried out without a solvent or in an excess of the compound of general formula V used.
  • [0064]
    If according to the invention a compound of general formula I is obtained which contains an amino, alkylamino or imino group, this may be converted by acylation or sulfonylation into a corresponding acyl or sulfonyl compound of general formula I or
  • [0000]
    if a compound of general formula I is obtained which contains an amino, alkylamino or imino group, this may be converted by alkylation or reductive alkylation into a corresponding alkyl compound of general formula I or
  • [0000]
    if a compound of general formula I is obtained which contains a carboxy or hydroxyphosphoryl group, this may be converted by esterification into a corresponding ester of general formula I or
  • [0000]
    if a compound of general formula I is obtained which contains a carboxy or ester group, this may be converted by reaction with an amine into a corresponding amide of general formula I.
  • [0065]
    The subsequent esterification is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane or most advantageously in a corresponding alcohol, optionally in the presence of an acid such as hydrochloric acid or in the presence of a dehydrating agent, e.g., in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, phosphorus trichloride, phosphorus pentoxide, N,N′-dicyclohexylcarbodiimide, N,N′-dicyclohexylcarbodiimide/N-hydroxysuccinimide or 1-hydroxybenzotriazole and optionally additionally in the presence of 4-dimethylamino-pyridine, N,N′-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, conveniently at temperatures between 0° C. and 150° C., preferably at temperatures between 0° C. and 80° C.
  • [0066]
    The subsequent ester formation may also be carried out by reacting a compound which contains a carboxy or hydroxyphosphoryl group with a corresponding alkyl halide.
  • [0067]
    The subsequent acylation or sulfonylation is conveniently carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane with a corresponding acyl or sulfonyl derivative optionally in the presence of a tertiary organic base or in the presence of an inorganic base or in the presence of a dehydrating agent, e.g., in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, phosphorus trichloride, phosphorus pentoxide, N,N′-dicyclohexylcarbodiimide, N,N′-dicyclohexylcarbodiimide/N-hydroxysuccinimide or 1-hydroxybenzotriazole and optionally also in the presence of 4-dimethylamino-pyridine, N,N′-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, expediently at temperatures between 0° C. and 150° C., preferably at temperatures between 0° C. and 80° C.
  • [0068]
    The subsequent alkylation is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane with an alkylating agent such as a corresponding halide or sulfonic acid ester, e.g., with methyl iodide, ethyl bromide, dimethyl sulfate or benzyl chloride, optionally in the presence of a tertiary organic base or in the presence of an inorganic base, expediently at temperatures between 0° C. and 150° C., preferably at temperatures between 0° C. and 100° C.
  • [0069]
    The subsequent reductive alkylation is carried out with a corresponding carbonyl compound such as formaldehyde, acetaldehyde, propionaldehyde, acetone or butyraldehyde in the presence of a complex metal hydride such as sodium borohydride, lithium borohydride, sodium triacetoxyborohydride or sodium cyanoborohydride, expediently at a pH of 6-7 and at ambient temperature or in the presence of a hydration catalyst, e.g., with hydrogen in the presence of palladium/charcoal, at a hydrogen pressure of 1 to 5 bar. The methylation can also be carried out in the presence of formic acid as reduction agent at elevated temperatures, e.g., at temperatures between 60° C. and 120° C.
  • [0070]
    The subsequent amide formation is carried out by reacting a corresponding reactive carboxylic acid derivative with a corresponding amine, optionally in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, whilst the amine used may simultaneously serve as solvent, optionally in the presence of a tertiary organic base or in the presence of an inorganic base or with a corresponding carboxylic acid in the presence of a dehydrating agent, e.g., in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, N,N′-dicyclohexylcarbodiimide, N,N′-dicyclohexylcarbodiimide/N-hydroxysuccinimide or 1-hydroxybenzotriazole and optionally also in the presence of 4-dimethylaminopyridine, N,N′-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, expediently at temperatures between 0° C. and 150° C., preferably at temperatures between 0 and 80° C.
  • [0071]
    In the reactions described hereinbefore, any reactive groups present such as hydroxy, carboxy, phosphono, O-alkyl-phosphono, amino, alkylamino or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.
  • [0072]
    For example, a protecting group for a hydroxy group may be a trimethylsilyl, acetyl, benzoyl, methyl, ethyl, tert-butyl, trityl, benzyl or tetrahydropyranyl group, protecting groups for a carboxy group may be a trimethylsilyl, methyl, ethyl, tert-butyl, benzyl or tetrahydropyranyl group,
  • [0000]
    protecting groups for a phosphono group may be an alkyl group such as the methyl, ethyl, isopropyl or n-butyl group, the phenyl or benzyl group, and
  • [0073]
    protecting groups for an amino, alkylamino or imino group may be a formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and additionally, for the amino group, a phthalyl group.
  • [0074]
    Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g., in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide or aprotically, e.g., in the presence of iodotrimethylsilane, at temperatures between 0° C. and 120° C., preferably at temperatures between 10° C. and 100° C.
  • [0075]
    However, a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example hydrogenolytically, e.g., with hydrogen in the presence of a catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0° C. and 100° C., but preferably at temperatures between 20° C. and 60° C., and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar. A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisole.
  • [0076]
    A tert-butyl or tert-butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid or by treating with iodotrimethylsilane optionally using a solvent such as methylene chloride, dioxane, methanol or diethyl ether.
  • [0077]
    A trifluoroacetyl group is preferably cleaved by treating with an acid such as hydrochloric acid, optionally in the presence of a solvent such as acetic acid at temperatures between 50° C. and 120° C. or by treating with sodium hydroxide solution optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0° C. and 50° C.
  • [0078]
    A phthalyl group is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene/water or dioxane at temperatures between 20° C. and 50° C.
  • [0079]
    A single alkyl group may be cleaved from an O,O′-dialkylphosphono group with sodium iodide, for example, in a solvent such as acetone, methyl ethyl ketone, acetonitrile or dimethylformamide at temperatures between 40° C. and 150° C., but preferably at temperatures between 60° C. and 100° C.
  • [0080]
    Both alkyl groups may be cleaved from an O,O′-dialkylphosphono group with iodotrimethylsilane, bromotrimethylsilane or chlorotrimethylsilane/sodium iodide, for example, in a solvent such as methyl chloride, chloroform or acetonitrile at temperatures between 0° C. and the boiling temperature of the reaction mixture, but preferably at temperatures between 20° C. and 60° C.
  • [0081]
    Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for example, cis/trans mixtures may be resolved into their cis and trans isomers, and compounds with at least one optically active carbon atom may be separated into their enantiomers.
  • [0082]
    Thus, for example, the cis/trans mixtures may be resolved by chromatography into the cis and trans isomers thereof, the compounds of general formula I obtained which occur as racemates may be separated by methods known per se (cf. N. L. Allinger and E. L. Eliel in “Topics in Stereochemistry”, Vol. 6, Wiley Interscience, 1971) into their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g., by chromatography and/or fractional crystallization, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.
  • [0083]
    The enantiomers are preferably separated by column separation on chiral phases or by recrystallization from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g., esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g., on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g., the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulfonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+) or (−)-menthol and an optically active acyl group in amides, for example, may be a (+)- or (−)-menthyloxycarbonyl.
  • [0084]
    Furthermore, the compounds of formula I may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
  • [0085]
    Moreover, if the new compounds of formula I thus obtained contain a carboxy, hydroxyphosphoryl, sulfo or 5-tetrazolyl group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include for example sodium hydroxide, potassium hydroxide, arginine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
  • [0086]
    The compounds of general formulae II to V used as starting materials are known from the literature in some cases or may be obtained by methods known from the literature (cf. Examples I to VII).
  • [0087]
    For example, a starting compound of general formula I is obtained by reacting a 7-fluoro-6-nitro compound correspondingly substituted in the 4 position with a corresponding alkoxide and subsequently reducing the nitro compound thus obtained or
  • [0088]
    a starting compound of general formula IV is obtained by reacting a 7-fluoro-6-nitro compound correspondingly substituted in the 4 position with a corresponding alkoxide, subsequently reducing the nitro compound thus obtained and then acylating with a corresponding compound.
  • [0089]
    As already mentioned hereinbefore, the compounds of general formula I according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by the Epidermal Growth Factor receptor (EGF-R), whilst this may be achieved for example by inhibiting ligand bonding, receptor dimerization or tyrosine kinase itself. It is also possible to block the transmission of signals to components located further down.
  • [0090]
    The biological properties of the new compounds were investigated as follows:
  • [0091]
    The inhibition of the EGF-R-mediated signal transmission can be demonstrated e.g., with cells which express human EGF-R and whose survival and proliferation depend on stimulation by EGF or TGF-alpha. A cell line of murine origin dependent on interleukin-3-(IL-3) which was genetically modified to express functional human EGF-R was used here. The proliferation of these cells known as F/L-HERc can therefore be stimulated either by murine IL-3 or by EGF (cf. T. von Rüden et al., EMBO J. 7, 2749-2756 (1988) and J. H Pierce et al., Science 239, 628-631 (1988)).
  • [0092]
    The starting material used for the F/L-HERc cells was the cell line FDC-P1, the production of which has been described by T. M. Dexter et al., J. Exp. Med. 152, 1036-1047 (1980). Alternatively, however, other growth-factor-dependent cells may also be used (cf., for example, J. H. Pierce et al., Science 239, 628-631 (1988); H. Shibuya et al., Cell 70, 57-67 (1992); and W. S. Alexander et al., EMBO J. 10, 3683-3691 (1991)). For expressing the human EGF-R cDNA (cf. Ullrich, A. et al. in Nature 309, 418-425 (1984)) recombinant retroviruses were used as described by T. von Rüden et al., EMBO J. 7, 2749-2756 (1988), except that the retroviral vector LXSN (cf. A. D. Miller et al., BioTechniques 7, 980-990 (1989)) was used for the expression of the EGF-R cDNA and the line GP+E86 (cf. D. Markowitz et al., J. Virol. 62, 1120-1124 (1988)) was used as the packaging cell.
  • [0093]
    The test was performed as follows:
  • [0094]
    F/L-HERc cells were cultivated in RPMI/1640 medium (BioWhittaker), supplemented with 10% fetal calf serum (FCS, Boehringer Mannheim), 2 mM glutamine (BioWhittaker), standard antibiotics and 20 ng/ml of human EGF (Promega), at 37° C. and 5% CO2—In order to investigate the inhibitory activity of the compounds according to the invention, 1.5×104 cells per well were cultivated in triplicate in 96-well dishes in the above medium (200 μl), the cell proliferation being stimulated with either EGF (20 ng/ml) or murine IL-3. The IL-3 used was obtained from culture supernatants of the cell line X63/0 mL-3 (cf. H. Karasuyama et al., Eur. J. Immunol. 18, 97-104 (1988)). The compounds according to the invention were dissolved in 100% dimethylsulfoxide (DMSO) and added to the cultures in various dilutions, the maximum DMSO concentration being 1%. The cultures were incubated for 48 hours at 37° C.
  • [0095]
    In order to determine the inhibitory activity of the compounds according to the invention the relative cell number was measured in O.D. units using the Cell Titer 96™ Aqueous Non-Radioactive Cell Proliferation Assay (Promega). The relative cell number was calculated as a percentage of the control (F/LHERc cells without inhibitor) and the concentration of active substance which inhibits the proliferation of the cells by 50% (IC50) was derived therefrom. The following results were obtained:
    Compound Inhibition of EGF-Dependent Proliferation
    (Example No.) IC50 [nM]
    1 <0.35
    2(3) 0.35
    1(7) <0.5
    3 5
    3(1) 0.2
  • [0096]
    The compounds of general formula I according to the invention thus inhibit signal transduction by tyrosine kinases, as demonstrated by the example of the human EGF receptor, and are therefore useful for treating pathophysiological processes caused by hyperfunction of tyrosine kinases. These are e.g., benign or malignant tumors, particularly tumors of epithelial and neuroepithelial origin, metastasization and the abnormal proliferation of vascular endothelial cells (neoangiogenesis).
  • [0097]
    The compounds according to the invention are also useful for preventing and treating diseases of the airways and lungs which are accompanied by increased or altered production of mucus caused by stimulation by tyrosine kinases, e.g., in inflammatory diseases of the airways such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, α1-antitrypsin deficiency, or coughs, pulmonary emphysema, pulmonary fibrosis and hyperreactive airways.
  • [0098]
    The compounds are also suitable for treating diseases of the gastrointestinal tract and bile duct and gall bladder which are associated with disrupted activity of the tyrosine kinases, such as may be found e.g., in chronic inflammatory changes such as cholecystitis, Crohns' disease, ulcerative colitis, and ulcers in the gastrointestinal tract or such as may occur in diseases of the gastrointestinal tract which are associated with increased secretions, such as Ménétrier's disease, secreting adenomas and protein loss syndrome.
  • [0099]
    In addition, the compounds of general formula I and the physiologically acceptable salts thereof may be used to treat other diseases caused by abnormal function of tyrosine kinases, such as e.g., epidermal hyperproliferation (psoriasis), inflammatory processes, diseases of the immune system, hyperproliferation of hematopoietic cells, etc.
  • [0100]
    By reason of their biological properties the compounds according to the invention may be used on their own or in conjunction with other pharmacologically active compounds, for example in tumour therapy, in monotherapy or in conjunction with other anti-tumour therapeutic agents, for example in combination with topoisomerase inhibitors (e.g., etoposide), mitosis inhibitors (e.g., vinblastine), compounds which interact with nucleic acids (e.g., cis-platin, cyclophosphamide, adriamycin), hormone antagonists (e.g., tamoxifen), inhibitors of metabolic processes (e.g., 5-FU etc.), cytokines (e.g., interferons), antibodies, etc. For treating respiratory tract diseases, these compounds may be used on their own or in conjunction with other therapeutic agents for the airways, such as substances with a secretolytic, broncholytic and/or antiinflammatory activity. For treating diseases in the region of the gastrointestinal tract, these compounds may also be administered on their own or in conjunction with substances having an effect on motility or secretion. These combinations may be administered either simultaneously or sequentially.
  • [0101]
    These compounds may be administered either on their own or in conjunction with other active substances by intravenous, subcutaneous, intramuscular, intraperitoneal or intranasal route, by inhalation or transdermally or orally, whilst aerosol formulations are particularly suitable for inhalation.
  • [0102]
    For pharmaceutical use the compounds according to the invention are generally used for warm-blooded vertebrates, particularly humans, in doses of 0.01-100 mg/kg of body weight, preferably 0.1-15 mg/kg. For administration they are formulated with one or more conventional inert carriers and/or diluents, e.g., with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, stearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof in conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions, solutions, sprays or suppositories.
  • [0103]
    The following Examples are intended to illustrate the present invention without restricting it:
  • [0000]
    Preparation of the Starting Compounds:
    • EXAMPLE I 6-Amino-4-[(3-bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]quinazoline
  • [0104]
    1.00 g of 4-[(3-bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-nitroquinazoline is dissolved in 16 ml of water, 35 ml of ethanol and 1.3 ml of glacial acetic acid and heated to boiling. Then 540 mg of iron powder are added with stirring. The reaction mixture is refluxed for about another 35 minutes. For working up the cooled reaction mixture is diluted with 15 ml of ethanol, made alkaline with 15 N sodium hydroxide solution, combined with 20 g of Extrelute and stirred for about 20 minutes. The precipitate formed is suction filtered and washed with 200 ml of warm ethanol. The filtrate is concentrated by evaporation, mixed with about 30 ml of water and extracted 3× with 70 ml of methylene chloride/methanol (9:1) each time. The combined extracts are dried over sodium sulfate and concentrated by evaporation, leaving a beige solid. Yield: 716 mg (76% of theory); melting point: 191° C.-198° C.; mass spectrum (ESI+): m/z=470, 472 [M+H]+.
  • [0105]
    The following compounds are obtained analogously to Example I:
    • (1) 6-Amino-4-[(3-bromophenyl)amino]-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline
  • [0107]
    Melting point: 197° C.; mass spectrum (ESI+): m/z=456, 458 [M+H]+.
    • (2) 6-Amino-4-[(3-bromophenyl)amino]-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
  • [0109]
    Melting point: 207° C.-208° C.; mass spectrum (ESI+): m/z=442, 444 [M+H]+.
    • (3) 6-Amino-4-[(3-bromophenyl)amino]-7-[(1-methylpiperidin-4-yl)oxy]quinazoline
  • [0111]
    Melting point: 170° C.; mass spectrum (ESI+): m/z=428, 430 [M+H]+.
    • (4) 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-cyclopropylmethoxyquinazoline
  • [0113]
    Melting point: 209° C.; Rf value: 0.68 (silica gel, ethyl acetate).
    • (5) 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-cyclobutyloxyquinazoline
  • [0115]
    Rf value: 0.32 (silica gel, cyclohexane/ethyl acetate=3:4); mass spectrum (ESI+): m/z=359, 361 [M+H]+.
    • (6) 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-cyclopentyloxyquinazoline
  • [0117]
    Rf value: 0.33 (silica gel, cyclohexane/ethyl acetate=1:1); mass spectrum (ESI+): m/z=373, 375 [M+H]+.
    • (7) 6-Amino-4-[(R)-(1-phenylethyl)amino]-7-cyclobutyloxyquinazoline
  • [0119]
    Rf value: 0.28 (silica gel, ethyl acetate); mass spectrum (ESI+): m/z=335 [M+H]+.
    • (8) 6-Amino-4-[(R)-(1-phenylethyl)amino]-7-cyclopropylmethoxyquinazoline
  • [0121]
    Rf value: 0.54 (silica gel, ethyl acetate); mass spectrum (ESI+): m/z=335 [M+H]+.
    • (9) 6-Amino-4-[(R)-(1-phenylethyl)amino]-7-cyclopentyloxyquinazoline
  • [0123]
    Rf value: 0.20 (silica gel, ethyl acetate); mass spectrum (ESI+): m/z=349 [M+H]+.
    • (10) 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]quinazoline
  • [0125]
    Rf value: 0.12 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=444, 446 [M+H]+.
    • (11) 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydrofuran-2-yl)methoxy]quinazoline
  • [0127]
    Melting point: 162° C.-164° C.; Rf value: 0.55 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI−): m/z=387, 389 [M−H]−.
    • (12) 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-[(s)-(tetrahydrofuran-3-yl)oxy]quinazoline
  • [0129]
    Rf value: 0.27 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI−): m/z=373, 375 [M−H]−.
    • (13) 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydropyran-4-yl)oxy]quinazoline
  • [0131]
    Rf value: 0.41 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI−): m/z=387, 389 [M−H]−.
    • (14) 6-Amino-4-[(R)-(1-phenylethyl)amino]-7-[2-(azetidin-1-yl)-ethoxy]quinazoline
  • [0133]
    Rf value: 0.37 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=364 [M+H]+.
    • (15) 6-Amino-4-[(R)-(1-phenylethyl)amino]-7-[2-(4-methyl-perhydro-1,4-diazepin-1-yl)-ethoxy]quinazoline
  • [0135]
    Rf value: 0.10 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:1); mass spectrum (ESI+): m/z=421 [M+H]+.
    • (16) 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-methyl-perhydro-1,4-diazepin-1-yl)propyloxy]quinazoline
  • [0137]
    Rf value: 0.09 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=459, 461 [M+H]+.
    • (17) 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(azetidin-1-yl)propyloxy]quinazoline
  • [0139]
    Rf value: 0.11 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=402, 404 [M+H]+.
    • EXAMPLE II 4-[(3-Bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-nitroquinazoline
  • [0140]
    To a solution of 1.45 g of 3-(1-methylpiperidin-4-yl)propan-1-ol in 40 ml of tetrahydrofuran are added 360 mg of sodium hydride. The white suspension formed is stirred for 15 minutes at 65° C., cooled and mixed with 1.45 g of 4-[(3-bromophenyl)amino]-7-fluoro-6-nitroquinazoline, whereupon the mixture suddenly turns dark red. The reaction mixture is stirred first for 10 minutes at ambient temperature, then for 45 minutes at 65° C. As the reaction is not yet complete, a further 150 mg of sodium hydride are added and the mixture is stirred for a further 45 minutes at 65° C. The solvent is distilled off using a rotary evaporator and the brown residue is stirred with 50 ml of ice water. The aqueous phase is extracted with methylene chloride. The combined extracts are washed with water, dried over sodium sulfate and concentrated by evaporation. The crude product is purified by chromatography over a silica gel column with methylene chloride/methanol/concentrated ammonia solution (90:10:0.05). Yield: 1.30 g of (65% of theory); Rf value: 0.28 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=500, 502 [M+H]+.
  • [0141]
    The following compounds are prepared analogously to Example II:
    • (1) 4-[(3-Bromophenyl)amino]-7-[2-(1-methylpiperidin-4-yl)ethoxy]-6-nitroquinazoline
  • [0143]
    Melting point: 152° C.; mass spectrum (ESI+): m/z=486, 488 [M+H]+.
    • (2) 4-[(3-Bromophenyl)amino]-7-[(1-methylpiperidin-4-yl)methoxy]-6-nitroquinazoline
  • [0145]
    Melting point: 205° C.-207° C.; mass spectrum (ESI+): m/z=472, 474 [M+H]+.
    • (3) 4-[(3-Bromophenyl)amino]-7-[(1-methylpiperidin-4-yl)oxy]-6-nitroquinazoline
  • [0147]
    Melting point: 219° C.; mass spectrum (ESI+): m/z=458, 460 [M+H]+.
    • (4) 4-[(3-Chloro-4-fluorophenyl)amino]-7-cyclopropylmethoxy-6-nitroquinazoline
  • [0149]
    Carried out in dimethylformamide with potassium tert-butoxide as base. Melting point: 211° C.-213° C.; mass spectrum (ESI+): m/z=389, 391 [M+H]+.
    • (5) 4-[(3-Chloro-4-fluorophenyl)amino]-7-cyclobutyloxy-6-nitroquinazoline
  • [0151]
    Carried out in dimethylformamide with potassium tert-butoxide as base. Melting point: 235° C.; Rf value: 0.65 (silica gel, cyclohexane/ethyl acetate=3:4).
    • (6) 4-[(3-Chloro-4-fluorophenyl)amino]-7-cyclopentyloxy-6-nitroquinazoline
  • [0153]
    Carried out in dimethylformamide with potassium tert-butoxide as base. Melting point: 230° C.; mass spectrum (ESI+): m/z=403, 405 [M+H]+.
    • (7) 4-[(R)-(1-Phenylethyl)amino]-7-cyclobutyloxy-6-nitroquinazoline
  • [0155]
    Carried out in dimethylformamide with potassium tert-butoxide as base. Melting point: 108° C.-110° C.; Rf value: 0.54 (silica gel, ethyl acetate).
    • (8) 4-[(R)-(1-Phenylethyl)amino]-7-cyclopropylmethoxy-6-nitroquinazoline
  • [0157]
    Carried out in dimethylformamide with potassium tert-butoxide as base. Melting point: 155° C.; Rf value: 0.24 (silica gel, cyclohexane/ethyl acetate=1:1).
    • (9) 4-[(R)-(1-Phenylethyl)amino]-7-cyclopentyloxy-6-nitroquinazoline
  • [0159]
    Carried out in dimethylformamide with potassium tert-butoxide as base. Rf value: 0.24 (silica gel, petroleum ether/ethyl acetate=1:1); mass spectrum (ESI+): m/z=379 [M+H]+.
    • (10) 4-[(3-Chloro-4-fluorophenyl)amino]-6-nitro-7-[3-(1-methylpiperidin-4-yl)propyloxy]quinazoline
  • [0161]
    Rf value: 0.30 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=474, 476 [M+H]+.
    • (11) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[(tetrahydrofuran-2-yl)methoxy]-6-nitroquinazoline
  • [0163]
    Carried out in dimethylformamide with potassium tert-butoxide as base. Rf value: 0.47 (silica gel, ethyl acetate); mass spectrum (ESI+): m/z=417, 419 [M−H]−.
    • (12) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[(s)-(tetrahydrofuran-3-yl)oxy]-6-nitroquinazoline
  • [0165]
    Carried out in dimethylformamide with potassium tert-butoxide as base. Rf value: 0.45 (silica gel, ethyl acetate); mass spectrum (ESI−): m/z=403, 405 [M−H]−.
    • (13) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[(tetrahydropyran-4-yl)oxy]-6-nitroquinazoline
  • [0167]
    Carried out in dimethylformamide with potassium tert-butoxide as base. Rf value: 0.41 (silica gel, ethyl acetate); mass spectrum (ESI−): m/z=417, 419 [M−H]−.
    • (14) 4-[(R)-(1-Phenylethyl)amino]-7-[2-(tetrahydropyran-2-yloxy)ethoxy]-6-nitroquinazoline
  • [0169]
    Rf value: 0.12 (silica gel, cyclohexane/ethyl acetate=1:1); mass spectrum (ESI+): m/z=439 [M+H]+.
    • (15) 4-[(3-Chloro-4-fluorophenyl)amino]-7-{3-[(tert-butyldimethylsilyl)oxy]propyloxy}-6-nitroquinazoline (carried out in dimethylformamide with potassium tert-butoxide as base)
  • [0171]
    Rf value: 0.87 silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=507, 509 [M+H]+.
    • EXAMPLE III 4-[(R)-(1-Phenylethyl)amino]-6-nitro-7-fluoroquinazoline
  • [0172]
    A solution of 74 ml of (R)-1-phenylethylamine in 100 ml of dioxane is dropped into 108.8 g of 4-chloro-6-nitro-7-fluoro-quinazoline in 800 ml of methylene chloride with cooling. The reaction mixture is washed with water after stirring overnight at room temperature, the organic phase is separated, dried and evaporated. The obtained residue is purified by chromatography over a silica gel column (petroleum ether/ethyl acetate=1:1). Yield: 52.9 g (35% of theory); melting point: 203° C.; mass spectrum (ESI+): m/z=313 [M+H]+.
    • EXAMPLE IV 4-[(R)-(1-Phenylethyl)amino]-7-[2-(azetidin-1-yl)ethoxy]-6-nitroquinazoline
  • [0173]
    221 mg of dried potassium carbonate and 50 mg of sodium iodide were given to 600 mg of 4-[(R)-(1-phenylethyl)amino]-7-[2-methanesulfonyloxyethoxy]-6-nitroquinazoline and 0.34 ml of azetidine in 5.0 ml of acetonitrile. The reaction mixture was heated up to 70° C. with stirring. Subsequently 3 ml of acetonitrile were added after one hour and the mixture was stirred for further about 40 hours at 70° C. The solvent was removed in vacuo and the obtained residue was mixed with ice water. The precipitate was suction filtered and dried. The aqueous phase was extracted with methylene chloride and evaporated. The combined precipitates were dissolved in ethyl acetate and stirred together with a little of silica gel and 120 mg of charcoal for further purification. The obtained suspension was filtered and evaporated yielding a yellow resin. Yield: 518 mg (95% of theory); Rf value: 0.40 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=394 [M+H]+.
  • [0174]
    The following compounds were obtained analogously to Example IV:
    • (1) 4-[(R)-(1-Phenylethyl)amino]-7-[2-(4-methyl-perhydro-1,4-diazepin-1-yl)-ethoxy]-6-nitroquinazoline
  • [0176]
    Rf value: 0.30 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=451 [M+H]+.
    • (2) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-methyl-perhydro-1,4-diazepin-1-yl)propyloxy]-6-nitroquinazoline
  • [0178]
    Rf value: 0.34 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=80:20:0.1); mass spectrum (ESI+): m/z=489, 491 [M+H]+.
    • (3) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(azetidin-1-yl)propyloxy]-6-nitroquinazoline
  • [0180]
    Rf value: 0.23 silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=432, 434 [M+H]+.
    • EXAMPLE V 4-[(R)-(1-Phenylethyl)amino]-7-[2-(methanesulfonyloxy)ethoxy]-6-nitroquinazoline
  • [0181]
    A solution of 1.79 ml methanesulfonic acid chloride in 10 ml of methylene chloride was dropped into a mixture of 8.08 g of 4-[(R)-(1-phenylethyl)amino]-7-(2-hydroxyethoxy)-6-nitroquinazoline and 4.53 ml of ethyl-diisopropylamine in 90 ml of methylene chloride with ice cooling. The reaction mixture was stirred about one hour at room temperature whereby further 0.4 ml of methanesulfonic acid chloride and 0.5 ml of ethyldiisopropylamine were added to complete the reaction. Subsequently the reaction mixture was mixed with ice water and stirred after addition of saturated aqueous sodium carbonate solution. The organic phase was separated, washed with water, dried over magnesium sulfate and evaporated. The obtained dark resinous residue was crystallized by stirring with little tert-butyl methyl ether, suction filtered and dried in an exsiccator. Yield: 9.72 g (99% of theory); melting point: 128° C.-134° C.; mass spectrum (ESI−): m/z=431 [M−H]−.
  • [0182]
    The following compound was obtained analogously to Example V:
    • (1) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(methanesulfonyloxy)propyloxy]-6-nitroquinazoline
  • [0184]
    Rf value: 0.75 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=471, 473 [M+H]+.
    • EXAMPLE VI 4-[(R)-(1-Phenylethyl)amino]-7-(2-hydroxyethoxy)-6-nitroquinazoline
  • [0185]
    120 ml of methanol and 2 ml of concentrated hydrochloric acid were given to 8.05 g of 4-[(R)-(1-Phenylethyl)amino]-7-[2-(tetrahydropyran-2-yloxy)ethoxy]-6-nitroquinazoline. After stirring for 1.5 hours at 50° C. the reaction mixture was neutralized with concentrated aqueous sodium carbonate solution and evaporated. The solid residue was dissolved in ethyl acetate and the obtained solution was washed with water, with concentrated aqueous sodium chloride solution, dried over magnesium sulfate solution and evaporated. The obtained yellow residue was stirred with 20 ml of tert-butyl methyl ether, suction filtered and dried in an exsiccator. Yield: 4.53 g (91% of theory); melting point: 192° C.-194° C.; mass spectrum (ESI−): m/z=353 [M−H]−.
    • EXAMPLE VII 4-[(3-Chloro-4-fluorophenyl)amino]-7-(3-hydroxypropyloxy)-6-nitroquinazoline
  • [0186]
    Prepared from 4-[(3-Chloro-4-fluorophenyl)amino]-7-{3-[(tert-butyl-dimethylsilyl)oxy]propyloxy}-6-nitroquinazoline by splitting off the protective silyl group with tetrabutyl ammonium fluoride in tetrahydrofuran. Yield: 94% of theory; Rf value: 0.61 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI−): m/z=391, 393 [M−H]−.
  • [0000]
    Preparation of the End Products:
    • EXAMPLE 1 4-[(3-Bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline
  • [0187]
    To a solution of 300 mg of 6-amino-4-[(3-bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]quinazoline in 7 ml of dichloromethane are added 0.28 ml of triethylamine. The reaction mixture is cooled to about −10° C. in an ice/sodium chloride cooling bath. Then a solution of 59 μl of acrylic acid chloride in 1 ml of tetrahydrofuran is added dropwise within 10 minutes. The cooling bath is removed and the mixture is stirred for a further 15 minutes at ambient temperature. For working up, the reaction mixture is poured on to 20 ml of ice water and mixed with 2-3 ml of 2 N sodium hydroxide solution, whereupon a light-colored precipitate is formed. The precipitate is suction filtered, washed with cold water and dissolved in dichloromethane. The solution is dried over sodium sulfate and concentrated by evaporation. The resin-like crude product is purified by chromatography over a silica gel column with methylene chloride/methanol/concentrated ammonia solution (90:10:0.5). Yield: 118 mg (35% of theory); Rf value: 0.35 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=524, 526 [M+H]+.
  • [0188]
    The following compounds are obtained analogously to Example 1:
    • (1) 4-[(3-Bromophenyl)amino]-7-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(vinylcarbonyl)amino]quinazoline
  • [0190]
    Melting point: 129° C.; mass spectrum (ESI+): m/z=510, 512 [M+H]+.
    • (2) 4-[(3-Bromophenyl)amino]-7-[(1-methylpiperidin-4-yl)methoxy]-6-[(vinylcarbonyl)amino]quinazoline
  • [0192]
    Melting point: 174° C.; mass spectrum (ESI+): m/z=496, 498 [M+H]+.
    • (3) 4-[(3-Bromophenyl)amino]-7-[(1-methylpiperidin-4-yl)oxy]-6-[(vinylcarbonyl)amino]quinazoline
  • [0194]
    Melting point: 166° C.; mass spectrum (ESI+): m/z=482, 484 [M+H]+.
    • (4) 4-[(3-Bromophenyl)amino]-7-[(1-methylpiperidin-4-yl)oxy]-6-[(1-oxo-2-buten-1-yl)amino]quinazoline
  • [0196]
    Rf value: 0.67 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=40:10:0.5); mass spectrum (ESI+): m/z=496, 498 [M+H]+.
    • (5) 4-[(3-Bromophenyl)amino]-7-[(1-methylpiperidin-4-yl)methoxy]-6-[(1-oxo-2-buten-1-yl)amino]quinazoline
  • [0198]
    Rf value: 0.45 (aluminium oxide, activity III; ethyl acetate/methanol=4:1); mass spectrum (EI): m/z=509, 511 [M]+.
    • (6) 4-[(3-Bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-[(3-ethoxycarbonyl-1-oxo-2-propen-1-yl)amino]quinazoline
  • [0200]
    Rf value: 0.28 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=596, 598 [M+H]+.
    • (7) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline
  • [0202]
    Rf value: 0.33 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=498, 500 [M+H]+.
    • (8) 4-[(R)-(1-Phenylethyl)amino]-7-[2-(azetidin-1-yl)-ethoxy]-6-[(vinylcarbonyl)amino]quinazoline Rf value: 0.60 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI−): m/z=416 [M−H]−.
    • (9) 4-[(R)-(1-Phenylethyl)amino]-7-[2-(4-methyl-perhydro-1,4-diazepin-1-yl)-ethoxy]-6-[(vinylcarbonyl)amino]quinazoline
  • [0205]
    Rf value: 0.37 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI−): m/z=473 [M−H]−.
    • (10) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-methyl-perhydro-1,4-diazepin-1-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline
  • [0207]
    Rf value: 0.29 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI+): m/z=513, 515 [M+H]+.
    • (11) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(azetidin-1-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline
  • [0209]
    Rf value: 0.39 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=90:10:0.1); mass spectrum (ESI−): m/z=454, 456 [M−H]−.
    • EXAMPLE 2 4-[(3-Bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-[(1-oxo-2,4-hexadien-1-yl)amino]quinazoline
  • [0210]
    To 31 mg of sorbic acid in 1 ml of tetrahydrofuran are added 40 μl of isobutyl chloroformate followed by 45 μl of N-methylmorpholine whilst cooling with an ice bath. The white suspension is stirred for one minute, then a solution of 100 mg of 6-amino-4-[(3-bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]quinazoline in 1.5 ml of pyridine is added. The ice bath is removed and the reaction mixture is stirred overnight. For working up, it is poured onto 20 ml of ice water, stirred for 30 minutes and adjusted to pH 9-10 with a few drops of 2 N sodium hydroxide solution. The aqueous phase is extracted with methylene chloride, the combined organic phases are dried over sodium sulfate and concentrated by evaporation. The resin-like crude product is purified by chromatography over an aluminium oxide column (activity III) with methylene chloride/methanol (99.5:0.5). Yield: 62 mg (52% of theory); Rf value: 0.29 (aluminium oxide, activity III; methylene chloride/methanol=98:2); mass spectrum (EI): m/z=563, 565 [M]+.
  • [0211]
    The following compounds are obtained analogously to Example 2:
    • (1) 4-[(3-Bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-[(1-oxo-2-buten-1-yl)amino]quinazoline
  • [0213]
    Rf value: 0.26 (aluminium oxide, activity III; methylene chloride/methanol=98:2); mass spectrum (ESI+): m/z=538, 540 [M+H]+.
    • (2) 4-[(3-Bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-[(3-phenyl-1-oxo-2-propen-1-yl)amino]quinazoline
  • [0215]
    Rf value: 0.26 (aluminium oxide, activity III; methylene chloride/methanol=98:2); mass spectrum (EI): m/z=599, 601 [M]+.
    • (3) 4-[(3-Bromophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-[(1-oxo-2-butyn-1-yl)amino]quinazoline
  • [0217]
    Rf value: 0.40 (aluminium oxide, activity III; methylene chloride/methanol=98:2); mass spectrum (ESI+): m/z=536, 538 [M+H]+.
    • EXAMPLE 3 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0218]
    To a solution of 640 mg of 4-bromo-2-butenoic acid in 10 ml of methylene chloride are added, at ambient temperature, 0.67 ml of oxalyl chloride and one drop of dimethylformamide. The reaction mixture is stirred for about another half hour at ambient temperature, until the development of gas has ceased. The acid chloride formed is substantially freed from solvent in vacuo using a rotary evaporator. Then the crude product is dissolved in 10 ml of methylene chloride and added dropwise, whilst cooling with an ice bath, to a mixture of 1.00 g of 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-7-cyclopropylmethoxyquinazoline and 1.60 ml of Hünig base in 50 ml of tetrahydrofuran. The reaction mixture is stirred for 1.5 hours in an ice bath and for a further 2 hours at ambient temperature. Then 2.90 ml of diethylamine are added and the mixture is stirred for 2.5 days at ambient temperature. To work it up, the reaction mixture is filtered and the filtrate is concentrated by evaporation. The filter residue is purified by chromatography over a silica gel column with ethyl acetate/methanol (19:1). Yield: 550 mg (40% of theory); melting point: 114° C.; mass spectrum (ESI+): m/z=498, 500 [M+H]+.
  • [0219]
    The following compounds are obtained analogously to Example 3:
    • (1) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0221]
    Rf value: 0.53 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI−): m/z=510, 512 [M−H]−.
    • (2) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-ethylpiperazin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0223]
    Rf value: 0.44 (silica gel, ethyl acetate/methanol/concentrated aqueous ammonia solution=9:1:0.1); mass spectrum (EI): m/z=538, 540 [M]+.
    • (3) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(2,6-dimethyl-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0225]
    Melting point: 160° C.; mass spectrum (ESI+): m/z=540, 542 [M+H]+.
    • (4) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0227]
    Melting point: 137° C.; mass spectrum (ESI+): m/z=470, 472 [M+H]+.
    • (5) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(1-oxido-thiomorpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0229]
    Melting point: 239° C.; mass spectrum (ESI+): m/z=544, 546 [M+H]+.
    • (6) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
  • [0231]
    Rf value: 0.45 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI+): m/z=512, 514 [M+H]+.
    • (7) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxyquinazoline
  • [0233]
    Melting point: 143° C.; Rf value: 0.45 (silica gel, ethyl acetate/methanol=9:1).
    • (8) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
  • [0235]
    Melting point: 111° C.; Rf value: 0.21 (silica gel, ethyl acetate/methanol=9:1).
    • (9) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxyquinazoline
  • [0237]
    Melting point: 105° C.; Rf value: 0.23 (silica gel, ethyl acetate/methanol=9:1).
    • (10) 4-[(R)-(1-Phenylethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
  • [0239]
    Rf value: 0.33 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI+): m/z=488 [M+H]+.
    • (11) 4-[(R)-(1-Phenylethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0241]
    Rf value: 0.37 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI+): m/z=488 [M+H]+.
    • (12) 4-[(R)-(1-Phenylethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxyquinazoline
  • [0243]
    Rf value: 0.35 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI+): m/z=502 [M+H]+.
    • (13) 4-[(R)-(1-Phenylethyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
  • [0245]
    Rf value: 0.26 (silica gel, ethyl acetate/methanol=4:1); mass spectrum (ESI+): m/z=474 [M+H]+.
    • (14) 4-[(R)-(1-Phenylethyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxyquinazoline
  • [0247]
    Rf value: 0.31 (silica gel, ethyl acetate/methanol=4:1); mass spectrum (ESI+): m/z=488 [M+H]+.
    • (15) 4-[(R)-(1-Phenylethyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0249]
    Rf value: 0.15 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI+): m/z=474 [M+H]+.
    • (16) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(1-methylpiperidin-4-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
  • [0251]
    Rf value: 0.28 (silica gel, ethyl acetate/methanol/concentrated aqueous ammonia solution=80:20:2); mass spectrum (ESI+): m/z=553, 555 [M+H]+.
    • (17) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[(R)-2-methoxymethylpyrrolidin-1-yl]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
  • [0253]
    Rf value: 0.33 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI+): m/z=540, 542 [M+H]+.
    • (18) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[(s)-2-methoxymethylpyrrolidin-1-yl]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
  • [0255]
    Melting point: 120° C.; mass spectrum (ESI+): m/z=540, 542 [M+H]+.
    • (19) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[bis-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
  • [0257]
    Rf value: 0.51 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI+): m/z=558, 560 [M+H]+.
    • (20) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-ethyl-N-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline Rf value: 0.33 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI+): m/z=528, 530 [M+H]+.
    • (21) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(piperidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0260]
    Rf value: 0.22 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI+): m/z=510, 512 [M+H]+.
    • (22) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(2-methylpiperidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0262]
    Rf value: 0.21 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI+): m/z=524, 526 [M+H]+.
    • (23) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(pyrrolidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0264]
    Rf value: 0.10 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI+): m/z=496, 498 [M+H]+.
    • (24) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-cyclopropylmethylpiperazin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0266]
    Melting point: 117° C.; mass spectrum (ESI+): m/z=565, 567 [M+H]+.
    • (25) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(2-methylpyrrolidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0268]
    Melting point: 108° C.-110° C.; Rf value: 0.27 (silica gel, ethyl acetate/methanol=9:1).
    • (26) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydropyran-4-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
  • [0270]
    Rf value: 0.29 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI−): m/z=538, 540 [M−H]−.
    • (27) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(cis-2,6-dimethylpiperidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0272]
    Rf value: 0.27 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI−): m/z=536, 538 [M−H]−.
    • (28) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(2,5-dimethylpyrrolidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0274]
    Rf value: 0.36 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI−): m/z=522, 524 [M−H]−.
    • (29) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(tetrahydrofuran-2-yl)methoxy]quinazoline
  • [0276]
    Rf value: 0.35 (silica gel, ethyl acetate/methanol/concentrated aqueous ammonia solution=9:1:0.1); mass spectrum (ESI−): m/z=526, 528 [M−H]−.
    • (30) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(s)-(tetrahydrofuran-3-yl)oxy]quinazoline
  • [0278]
    Melting point: 119° C.; mass spectrum (ESI−): m/z=512, 514 [M−H]−.
    • (31) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-diethylaminomethylpiperidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0280]
    Rf value: 0.20 (silica gel, methylene chloride/methanol=9:1); mass spectrum (ESI−): m/z=593, 595 [M−H]−.
    • (32) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N-methyl-N-cyclopropylmethyl-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0282]
    Rf value: 0.73 (silica gel, methylene chloride/methanol=9:1); mass spectrum (ESI+): m/z=510, 512 [M+H]+.
    • (33) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(2-methoxypropyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
  • [0284]
    The N-methyl-N-(2-methoxypropyl)amine used was prepared by reaction of 2-methoxypropionic acid chloride with methylamine and subsequent reduction with lithium aluminium hydride; melting point: 123° C.-125° C.; Rf value: 0.66 (silica gel, methylene chloride/methanol=9:1).
    • (34) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(3-methoxypropyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
  • [0286]
    Rf value: 0.66 (silica gel, methylene chloride/methanol=9:1); mass spectrum (ESI+): m/z=528, 530 [M+H]+.
    • (35) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-methoxypiperidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0288]
    Melting point: 129° C.-130° C.; Rf value: 0.20 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI−): m/z=538, 540 [M−H]−.
    • (36) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-hydroxypiperidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
  • [0290]
    Rf value: 0.30 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution=9:1:0.1); mass spectrum (ESI−): m/z=524, 526 [M−H]−.
    • (37) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(tetrahydropyran-4-yl)oxy]quinazoline
  • [0292]
    Rf value: 0.47 (silica gel, methylene chloride/methanol=9:1); mass spectrum (ESI−): m/z=528, 530 [M−H]−.
    • (38) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
  • [0294]
    Melting point: about 145° C. (decomp.); Rf value: 0.23 (silica gel, methylene chloride/methanol=15:1); Mass spectrum (ESI+): m/z=540, 542 [M+H]+.
    • (39) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydrofuran-3-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
  • [0296]
    The starting N-methyl-N-(3-tetrahydrofuranyl)amine was prepared by reaction of tetrahydrofuran-3-carboxylic acid with diphenyl phosphonate azide in benzyl alcohol and subsequent reduction of the obtained 3-(benzyloxycarbonylamino)tetrahydrofuran with lithium aluminium hydride. Melting point: 157° C.-159° C.; Rf value: 0.23 (silica gel, methylene chloride/methanol=15:1); mass spectrum (ESI+): m/z=526, 528 [M+H]+.
    • (40) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(1-methoxy-2-propyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
  • [0298]
    The starting N-methyl-N-(1-methoxy-2-propyl)amine was prepared by reductive amination of methoxyacetone with methylamine hydrochloride and sodium triacetoxyborohydride in the presence of sodium acetate. The reaction was carried out in tetrahydrofuran. Rf value: 0.38 (silica gel, ethyl acetate/methanol=9:1); mass spectrum (ESI+): m/z=528, 530 [M+H]+.
  • [0299]
    The following compounds may also be obtained analogously to the above Examples and other methods known from the literature:
    • (1) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (2) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dibutylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (3) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(piperidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (4) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(2,6-dimethylmorpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (5) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-methylpiperazin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (6) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-cyclopropylmethylpiperazin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (7) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-cyclopropylpiperazin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (8) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-methylsulfonylpiperazin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (9) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-acetylpiperazin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (10) 4-[(3-Chloro-4-fluorophenyl)amino]-6-[(4-{4-[(N,N-dimethylamino)carbonyl]piperazin-1-yl}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline
    • (11) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(pyrrolidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (12) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (13) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropylmethyl-N-methylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (14) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-butyn-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (15) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-butyn-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (16) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(piperidin-1-yl)-1-oxo-2-butyn-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (17) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-butyn-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (18) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-methylpiperazin-1-yl)-1-oxo-2-butyn-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (19) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-methylsulfonylpiperazin-1-yl)-1-oxo-2-butyn-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (20) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1,4-dioxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (21) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[(3-N,N-dimethylamino-propan-1-yl)amino]-1,4-dioxo-2-buten-1-yl}amino]-7-cyclopropylmethoxyquinazoline
    • (22) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({2-[(N,N-diethylamino)methyl]-1-oxo-2-propen-1-yl}amino]-7-cyclopropylmethoxyquinazoline
    • (23) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(2-methoxymethylpyrrolidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    • (24) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N,N-bis(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
    • (25) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxyethyl)-N-methylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
    • (26) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclobutylmethoxyquinazoline
    • (27) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentylmethoxyquinazoline
    • (28) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclohexylmethoxyquinazoline
    • (29) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-(2-cyclopropylethoxy)quinazoline
    • (30) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-(3-cyclopropylpropyloxy)quinazoline
    • (31) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[4-(tetrahydrofuran-3-yl)piperidin-1-yl]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
    • (32) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[4-(morpholin-4-yl)piperidin-1-yl]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
    • (33) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[4-(tetrahydrofuran-3-yl)piperazin-1-yl]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
    • (34) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[4-(tetrahydrofuran-2-ylmethyl)piperazin-1-yl]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
    • (35) 4-[(3-Chloro-4-fluorophenyl)amino]-6-[(4-{N-methyl-N-[1-(tetrahydrofuran-3-yl)piperidin-4-yl]amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline
    • (36) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[(s)-2-methoxymethylpyrrolidin-1-yl]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline
    • (37) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[(R)-2-methoxymethylpyrrolidin-1-yl]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline
    • (38) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[bis-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline
    • (39) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline
    • (40) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[(S)—N-methyl-N-(1-methoxy-2-propyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline
    • (41) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[(R)—N-methyl-N-(1-methoxy-2-propyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline
    • (42) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(1-methoxy-2-propyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
    • (43) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(2-methoxypropyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
    • (44) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(3-methoxypropyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
    • (45) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydrofuran-3-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
    • (46) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[(S)—N-methyl-N-(tetrahydrofuran-3-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline
    • (47) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[(R)—N-methyl-N-(tetrahydrofuran-3-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline
    • (48) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydropyran-4-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
    • (49) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydropyran-4-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline
    • (50) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-cyclopropylpiperazin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (51) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-cyclopropylmethylpiperazin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (52) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (53) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropylmethyl-N-methyl-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (54) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline
    • (55) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[(R)—N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino]-1-oxo-2-buten-1-yl}-amino)-7-cyclobutyloxyquinazoline
    • (56) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[(S)—N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino]-1-oxo-2-buten-1-yl}-amino)-7-cyclobutyloxyquinazoline
    • (57) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(pyrrolidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (58) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(2-methylpyrrolidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (59) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(2,5-dimethylpyrrolidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (60) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(piperidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (61) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(2-methylpiperidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (62) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(2,6-dimethylpiperidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (63) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-hydroxy-piperidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (64) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(4-methoxy-piperidin-1-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (65) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[4-(2-methoxyethyl)piperazin-1-yl]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline
    • (66) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(3-methyl-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (67) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(3,5-dimethyl-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxyquinazoline
    • (68) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-(tetrahydrofuran-3-yloxy)quinazoline
    • (69) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-(tetrahydropyran-4-yloxy)quinazoline
    • (70) 4-[(3-Chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-(tetrahydrofuran-2-ylmethoxy)quinazoline
    • (71) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(azetidin-1-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline
    • (72) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-methyl-homopiperazin-1-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline.
    EXAMPLE 4
  • [0372]
    Coated Tablets Containing 75 mg of Active Substance
    1 tablet core contains:
    active substance  75.0 mg
    calcium phosphate  93.0 mg
    corn starch  35.5 mg
    polyvinylpyrrolidone  10.0 mg
    hydroxypropylmethylcellulose  15.0 mg
    magnesium stearate  1.5 mg
    230.0 mg

    Preparation:
  • [0373]
    The active substance is mixed with calcium phosphate, corn starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose and half the specified amount of magnesium stearate. Blanks 13 mm in diameter are produced in a tablet-making machine and these are then rubbed through a screen with a mesh size of 1.5 mm using a suitable machine and mixed with the rest of the magnesium stearate. This granulate is compressed in a tablet-making machine to form tablets of the desired shape. Weight of core: 230 mg; die: 9 mm, convex. The tablet cores thus produced are coated with a film consisting essentially of hydroxypropylmethylcellulose. The finished film-coated tablets are polished with beeswax. Weight of coated tablet: 245 mg.
    • EXAMPLE 5
  • [0000]
    Tablets Containing 100 mg of Active Substance
  • [0374]
    Composition:
    1 tablet contains:
    active substance 100.0 mg
    lactose  80.0 mg
    corn starch  34.0 mg
    polyvinylpyrrolidone  4.0 mg
    magnesium stearate  2.0 mg
    220.0 mg

    Method of Preparation:
  • [0375]
    The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50° C. it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets. Weight of tablet: 220 mg; diameter: 10 mm, biplanar, facetted on both sides and notched on one side.
    • EXAMPLE 6
  • [0000]
    Tablets Containing 150 mg of Active Substance
  • [0376]
    Composition:
    1 tablet contains:
    active substance  50.0 mg
    powdered lactose  89.0 mg
    corn starch  40.0 mg
    colloidal silica  10.0 mg
    polyvinylpyrrolidone  10.0 mg
    magnesium stearate  1.0 mg
    300.0 mg

    Preparation:
  • [0377]
    The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45° C., are passed through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture. Weight of tablet: 300 mg; die: 10 mm, flat.
    • EXAMPLE 7
  • [0378]
    Hard Gelatine Capsules Containing 150 mg of Active Substance
    1 capsule contains:
    active substance 50.0 mg
    corn starch (dried) approx. 80.0 mg
    lactose (powdered) approx. 87.0 mg
    magnesium stearate 3.0 mg
    approx. 420.0 mg

    Preparation:
  • [0379]
    The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gelatine capsules. Capsule filling: approx. 320 mg; capsule shell: size 1 hard gelatine capsule.
    • EXAMPLE 8
  • [0380]
    Suppositories Containing 150 mg of Active Substance
    1 suppository contains:
    active substance  150.0 mg
    polyethyleneglycol 1500  550.0 mg
    polyethyleneglycol 6000  460.0 mg
    polyoxyethylene sorbitan monostearate  840.0 mg
    2,000.0 mg

    Preparation:
  • [0381]
    After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled molds.
    • EXAMPLE 9
  • [0382]
    Suspension Containing 50 mg of Active Substance
    100 ml of suspension contain:
    active substance  1.00 g
    carboxymethylcellulose-Na-salt  0.10 g
    methyl p-hydroxybenzoate  0.05 g
    propyl p-hydroxybenzoate  0.01 g
    glucose 10.00 g
    glycerol  5.00 g
    70% sorbitol solution 20.00 g
    flavoring  0.30 g
    dist. water ad 100 ml

    Preparation:
  • [0383]
    The distilled water is heated to 70° C. The methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of carboxymethylcellulose are dissolved therein with stirring. The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the sugar, the sorbitol solution and the flavoring have been added and dissolved, the suspension is evacuated with stirring to eliminate air. 5 ml of suspension contain 50 mg of active substance.
    • EXAMPLE 10
  • [0384]
    Ampoules Containing 10 mg Active Substance
    Composition:
    active substance 10.0 mg
    0.01 N hydrochloric acid q.s.
    double-distilled water ad 2.0 ml

    Preparation:
  • [0385]
    The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with common salt, filtered sterile and transferred into 2 ml ampoules.
    • EXAMPLE 11
  • [0386]
    Ampoules Containing 50 mg of Active Substance
    Composition:
    active substance 50.0 mg
    0.01 N hydrochloric acid q.s.
    double-distilled water ad 10.0 ml

    Preparation:
  • [0387]
    The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules.
    • EXAMPLE 12
  • [0388]
    Capsules for Powder Inhalation Containing 5 mg of Active Substance
    1 capsule contains:
    active substance  5.0 mg
    lactose for inhalation 15.0 mg
    20.0 mg

    Preparation:
  • [0389]
    The active substance is mixed with lactose for inhalation. The mixture is packed into capsules in a capsule-making machine (weight of the empty capsule approx. 50 mg). Weight of capsule: 70.0 mg; size of capsule=3.
    • EXAMPLE 13
  • [0390]
    Solution for Inhalation for Hand-Held Nebulizers Containing 2.5 mg Active Substance
    1 spray contains:
    active substance 2.500 mg
    benzalkonium chloride 0.001 mg
    1N hydrochloric acid q.s.
    ethanol/water (50/50) ad 15.000 mg

    Preparation:
  • [0391]
    The active substance and benzalkonium chloride are dissolved in ethanol/water (50/50). The pH of the solution is adjusted with 1N hydrochloric acid. The resulting solution is filtered and transferred into suitable containers for use in hand-held nebulizers (cartridges). Contents of the container: 4.5 g.

Claims (18)

  1. 1. Bicyclic heterocycles of general formula
    Figure US20070185091A1-20070809-C00005
    wherein
    Ra denotes a hydrogen atom or a C1-4-alkyl group,
    Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R1 to R3, whilst
    R1 and R2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom,
    a C1-4-alkyl, hydroxy, C1-4-alkoxy, C3-6-cycloalkyl, C4-6-cycloalkoxy, C2-5-alkenyl or
    C2-5-alkynyl group,
    an aryl, aryloxy, arylmethyl or arylmethoxy group,
    a C3-5-alkenyloxy or C3-5-alkynyloxy group, whilst the unsaturated moiety may not be linked to the oxygen atom,
    a C1-4-alkylsulfenyl, C1-4-alkylsulfinyl, C1-4-alkylsulfonyl, C1-4-alkylsulfonyloxy, trifluoromethylsulfenyl, trifluoromethylsulfinyl or trifluoromethylsulfonyl group,
    a methyl or methoxy group substituted by 1 to 3 fluorine atoms,
    an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms,
    a cyano or nitro group or an amino group optionally substituted by one or two C1-4-alkyl groups, wherein the substitutents may be identical or different, or
    R1 together with R2, if they are bound to adjacent carbon atoms, denote a —
    CH═CH—CH═CH, —CH═CH—NH or —CH═N—NH group and
    R3 denotes a hydrogen, fluorine, chlorine or bromine atom,
    a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group,
    X denotes a methine group substituted by a cyano group or a nitrogen atom,
    A denotes an imino group optionally substituted by a C1-4-alkyl group,
    B denotes a carbonyl or sulfonyl group,
    C denotes a 1,3-allenylene, 1,1- or 1,2-vinylene group which may be substituted in each case by one or two methyl groups or by a trifluoromethyl group,
    an ethynylene group or
    a 1,3-butadien-1,4-ylene group optionally substituted by 1 to 4 methyl groups or by a trifluoromethyl group,
    D denotes an alkylene, —CO-alkylene or —SO2-alkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, whilst the linking of the —CO-alkylene or —SO2-alkylene group to the adjacent group C in each case must take place via the carbonyl or sulfonyl group,
    a —CO—O-alkylene, —CO—NR4-alkylene or —SO2—NR4-alkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms, whilst the linking to the adjacent group C in each case must take place via the carbonyl or sulfonyl group, wherein
    R4 denotes a hydrogen atom or a C1-4-alkyl group,
    or, if D is bound to a carbon atom of the group E, it may also denote a bond
    or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulfonyl group,
    E denotes an amino, C1-4-alkylamino or di-(C1-4-alkyl)-amino group wherein the alkyl moieties may be identical or different,
    a C2-4-alkylamino group wherein the alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, whilst
    R5 denotes a hydroxy, C1-4-alkoxy, amino, C1-4-alkylamino or di-(C1-4-alkyl)-amino group,
    a 4- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups or
    a 6- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups wherein in each case a methylene group in position 4 is replaced by an oxygen or sulfur atom, by a sulfinyl, sulfonyl, imino or N—(C1-4-alkyl)-imino group,
    an N—(C1-4-alkyl)-N—(C2-4-alkyl)-amino group wherein the C2-4-alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, whilst R5 is as hereinbefore defined,
    a di-(C2-4-alkyl)-amino group wherein the two C2-4-alkyl moieties are substituted in each case in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, whilst the substitutents may be identical or different and R5 is as hereinbefore defined,
    a C3-7-cycloalkylamino or C3-7-cycloalkyl-C1-3-alkylamino group wherein in each case the nitrogen atom may be substituted by a further C1-4-alkyl group,
    an amino or C1-4-alkylamino group wherein in each case the nitrogen atom is substituted by a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, 1-(tetrahydrofuran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-4-yl)-piperidin-4-yl, 3-pyrrolidinyl, 3-piperidinyl, 4-piperidinyl, 3-hexahydro-azepinyl or 4-hexahydro-azepinyl group optionally substituted by 1 to 3 C1-4-alkyl groups,
    a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 C1-2-alkyl groups, which may be substituted by the group R5 either at a cyclic carbon atom or at one of the alkyl groups, whilst R5 is as hereinbefore defined,
    a piperidino group substituted by a tetrahydrofuranyl, tetrahydropyranyl or tetrahydrofuranylmethyl group,
    a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 C1-2-alkyl groups wherein a methylene group in each case is replaced in the 4 position by an oxygen or sulfur atom, by an imino group substituted by the group R6, or by a sulfinyl or sulfonyl group, whilst
    R6 denotes a hydrogen atom, a C1-4-alkyl, 2-methoxy-ethyl, 3-methoxy-propyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, formyl, C1-4-alkylcarbonyl, C1-4-alkylsulfonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group,
    an imidazolyl group optionally substituted by 1 to 3 methyl groups,
    a C5-7-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulfur atom, by an imino group substituted by the group R6, by a sulfinyl or sulfonyl group, whilst R6 is as hereinbefore defined,
    or D together with E denotes a hydrogen, fluorine or chlorine atom,
    a C1-4-alkyl group optionally substituted by 1 to 5 fluorine atoms,
    a C3-6-cycloalkyl group,
    an aryl, heteroaryl, C1-4-alkylcarbonyl or arylcarbonyl group,
    a carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group or
    a carbonyl which is substituted by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group may be replaced in the 4 position by an oxygen or sulfur atom, by an imino group substituted by the group R6, by a sulfinyl or sulfonyl group, whilst R6 is as hereinbefore defined, and
    Rc denotes a C4-7-cycloalkoxy or C3-7-cycloalkyl-C1-6-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C1-3-alkyl, hydroxy, C1-4-alkoxy, amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, pyrrolidino, piperidino, morpholino, piperazino, N—(C1-2-alkyl)-piperazino, hydroxy-C1-2-alkyl, C1-4-alkoxy-C1-2-alkyl, amino-C1-2-alkyl, C1-4-alkylamino-C1-2-alkyl, di-(C1-4-alkyl)-amino-C1-2-alkyl, pyrrolidino-C1-2-alkyl, piperidino-C1-2-alkyl, morpholino-C1-2-alkyl, piperazino-C1-2-alkyl or N—(C1-2-alkyl)-piperazino-C1-2-alkyl group, whilst the abovementioned monosubstituted cycloalkyl moieties may additionally be substituted by a C1-3-alkyl group,
    a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuranylmethoxy group,
    an C2-4-alkoxy group substituted in β-, γ-, or δ-position with regard to the oxygen atom by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,
    a 3-pyrrolidinyloxy, 2-pyrrolidinyl-C1-4-alkyloxy, 3-pyrrolidinyl-C1-4-alkyloxy, 3-piperidinyloxy, 4-piperidinyloxy, 2-piperidinyl-C1-4-alkyloxy, 3-piperidinyl-C1-4-alkyloxy, 4-piperidinyl-C1-4-alkyloxy, 3-hexahydro-azepinyloxy, 4-hexahydro-azepinyloxy, 2-hexahydro-azepinyl-C1-4-alkyloxy, 3-He-xahydro-azepinyl-C1-4-alkyloxy or 4-hexahydro-azepinyl-C1-4-alkyloxy group wherein in each case the cyclic nitrogen atom is substituted by the group R6, where R6 is as hereinbefore defined, whilst
    by the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which in each case may be monosubstituted by R7, mono-, di- or trisubstituted by R8 or monosubstituted by R7 and additionally mono- or disubstituted by R8, wherein the substitutents may be identical or different and
    R7 denotes a cyano, carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl, di-(C1-4-alkyl)-aminocarbonyl, C1-4-alkylsulfenyl, C1-4-alkylsulfinyl, C1-4-alkylsulfonyl, hydroxy, C1-4-alkylsulfonyloxy, trifluoromethyloxy, nitro, amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, C1-4-alkylcarbonylamino, N—(C1-4-alkyl)-C1-4-alkylcarbonylamino, C1-4-alkylsulfonylamino, N—(C1-4-alkyl)-C1-4-alkylsulfonylamino, aminosulfonyl, C1-4-alkylaminosulfonyl or di-(C1-4-alkyl)-aminosulfonyl group or a carbonyl group which is substituted by a 5- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulfur atom, by a sulfinyl, sulfonyl, imino or N—(C1-4-alkyl)-imino group, and
    R8 denotes a fluorine, chlorine, bromine or iodine atom, a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group or
    two groups R8, if they are bound to adjacent carbon atoms, together denote a C3-5-alkylene, methylenedioxy or 1,3-butadien-1,4-ylene group,
    and the heteroaryl groups mentioned in the definition of the abovementioned groups include a 5-membered heteroaromatic group which contains an imino group, an oxygen or sulfur atom or an imino group, an oxygen or sulfur atom and one or two nitrogen atoms, or
    a 6-membered heteroaromatic group which contains one, two or three nitrogen atoms,
    whilst the abovementioned 5-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups and the abovementioned 6-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups or by a fluorine, chlorine, bromine or iodine atom or by a trifluoromethyl, hydroxy, methoxy or ethoxy group,
    the tautomers, stereoisomers and salts thereof.
  2. 2. Bicyclic heterocycles of general formula I according to claim 1, wherein
    Ra denotes a hydrogen atom,
    Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R1 to R3, whilst
    R1 and R2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom,
    a C1-4-alkyl, hydroxy, C1-4-alkoxy, C3-6-cycloalkyl, C4-6-cycloalkoxy, C2-5-alkenyl or C2-5-alkynyl group,
    an aryl, aryloxy, arylmethyl or arylmethoxy group,
    a methyl or methoxy group substituted by 1 to 3 fluorine atoms,
    a cyano or nitro group and
    R3 denotes a hydrogen, fluorine, chlorine or bromine atom,
    a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group,
    X denotes a methine group substituted by a cyano group or a nitrogen atom,
    A denotes an imino group,
    B denotes a carbonyl or sulfonyl group,
    C denotes a 1,3-allenylene, 1,1- or 1,2-vinylene group,
    an ethynylene or 1,3-butadien-1,4-ylene group,
    D denotes an alkylene, —CO-alkylene or —SO2-alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, whilst the linking of the —CO-alkylene or —SO2-alkylene group to the adjacent group C in each case must take place via the carbonyl or sulfonyl group,
    a —CO—O-alkylene, —CO—NR4-alkylene or —SO2—NR4-alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms, whilst the linking to the adjacent group C in each case must take place via the carbonyl or sulfonyl group, wherein
    R4 denotes a hydrogen atom or a C1-4-alkyl group,
    or, if D is bound to a carbon atom of the group E, it may also denote a bond,
    or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulfonyl group,
    E denotes a di-(C1-4-alkyl)-amino group wherein the alkyl moieties may be identical or different,
    an N—(C1-4-alkyl)-N—(C2-4-alkyl)-amino group wherein the C2-4-alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, where
    R5 denotes a hydroxy, C1-4-alkoxy or di-(C1-4-alkyl)-amino group,
    a 4- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups or
    a 6- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups wherein in each case a methylene group in position 4 is replaced by an oxygen or sulfur atom, or by a sulfinyl, sulfonyl or N—(C1-4-alkyl)-imino group,
    a di-(C2-4-alkyl)-amino group wherein the two C2-4-alkyl moieties in each case are substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, wherein the substitutents may be identical or different and R5 is as hereinbefore defined,
    a C3-7-cycloalkylamino or C3-7-cycloalkyl-C1-3-alkylamino group wherein in each case the nitrogen atom is substituted by a further C1-4-alkyl group,
    a C1-4-alkylamino group wherein the nitrogen atom is substituted by a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, 1-(tetrahydrofuran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-4-yl)-piperidin-4-yl, N—(C1-2-alkyl)-3-pyrrolidinyl, N—(C1-2-alkyl)-3-piperidinyl, N—(C1-2-alkyl)-4-piperidinyl, N—(C1-2-alkyl)-3-hexahydro-azepinyl or N—(C1-2-alkyl)-4-hexahydro-azepinyl group,
    an 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups, which may be substituted either at a cyclic carbon atom or at one of the methyl groups by the group R5, where R5 is as hereinbefore defined,
    a piperidino group substituted by a tetrahydrofuranyl, tetrahydropyranyl or tetrahydrofuranylmethyl group,
    a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups wherein in each case a methylene group is replaced in the 4 position by an oxygen or sulfur atom, by an imino group substituted by the group R6, by a sulfinyl or sulfonyl group, whilst
    R6 denotes a C1-4-alkyl, 2-methoxy-ethyl, 3-methoxy-propyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, formyl, C1-4-alkylcarbonyl, C1-4-alkylsulfonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group,
    a C5-7-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulfur atom, by an imino group substituted by the group R6, or by a sulfinyl or sulfonyl group, where R6 is as hereinbefore defined,
    or D together with E denotes a hydrogen, fluorine or chlorine atom,
    a C1-4-alkyl group optionally substituted by 1 to 5 fluorine atoms,
    a C3-6-cycloalkyl group,
    an aryl, C1-4-alkylcarbonyl or arylcarbonyl group,
    a carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group or
    a carbonyl group which is substituted by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulfur atom, by an imino group substituted by the group R6, or by a sulfinyl or sulfonyl group, where R6 is as hereinbefore defined, and
    Rc denotes a C4-7-cycloalkoxy or C3-7-cycloalkyl-C1-6-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C1-3-alkyl, hydroxy, C1-4-alkoxy, di-(C1-4-alkyl)-amino, pyrrolidino, piperidino, morpholino, N—(C1-2-alkyl)-piperazino, hydroxy-C1-2-alkyl, C1-4-alkoxy-C1-2-alkyl, di-(C1-4-alkyl)-amino-C1-2-alkyl, pyrrolidino-C1-2-alkyl, piperidino-C1-2-alkyl, morpholino-C1-2-alkyl or N—(C1-2-alkyl)-piperazino-C1-2-alkyl group, whilst the abovementioned monosubstituted cycloalkyl moieties may additionally be substituted by a C1-3-alkyl group,
    a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuranylmethoxy group,
    an C2-4-alkoxy group substituted in β-, γ-, or δ-position with regard to the oxygen atom by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,
    a 3-pyrrolidinyloxy, 2-pyrrolidinyl-C1-4-alkyloxy, 3-pyrrolidinyl-C1-4-alkyloxy, 3-piperidinyloxy, 4-piperidinyloxy, 2-piperidinyl-C1-4-alkyloxy, 3-piperidinyl-C1-4-alkyloxy, 4-piperidinyl-C1-4-alkyloxy, 3-hexahydro-azepinyloxy, 4-hexahydro-azepinyloxy, 2-hexahydro-azepinyl-C1-4-alkyloxy, 3-hexahydro-azepinyl-C1-4-alkyloxy or 4-hexahydro-azepinyl-C1-4-alkyloxy group wherein in each case the cyclic nitrogen atom is substituted by the group R6, where R6 is as hereinbefore defined, whilst by the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which may in each case be monosubstituted by R7, mono-, di- or trisubstituted by R8 or monosubstituted by R7 and additionally mono- or disubstituted by R8, wherein the substitutents may be identical or different and
    R7 denotes a cyano, carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl, di-(C1-4-alkyl)-aminocarbonyl, C1-4-alkylsulfenyl, C1-4-alkylsulfinyl, C1-4-alkylsulfonyl, hydroxy, C1-4-alkylsulfonyloxy, trifluoromethyloxy, nitro, amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, C1-4-alkylcarbonylamino, N—(C1-4-alkyl)-C1-4-alkylcarbonylamino, C1-4-alkylsulfonylamino, N—(C1-4-alkyl)-C1-4-alkylsulfonylamino, aminosulfonyl, C1-4-alkylaminosulfonyl or di-(C1-4-alkyl)-aminosulfonyl group or a carbonyl group which is substituted by a 5- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group may be replaced in the 4 position by an oxygen or sulfur atom, by a sulfinyl, sulfonyl, imino or N—(C1-4-alkyl)-imino group, and
    R8 denotes a fluorine, chlorine, bromine or iodine atom, a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group or
    two groups R8, if they are bound to adjacent carbon atoms, together denote a C3-5-alkylene, methylenedioxy or 1,3-butadien-1,4-ylene group,
    the tautomers, stereoisomers and salts thereof.
  3. 3. Bicyclic heterocycles of general formula I according to claim 1, wherein
    Ra denotes a hydrogen atom,
    Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R1 and R2, where
    R1 and R2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine or bromine atom,
    a methyl, trifluoromethyl or methoxy group,
    X denotes a nitrogen atom,
    A denotes an imino group,
    B denotes a carbonyl group,
    C denotes a 1,2-vinylene group,
    an ethynylene or 1,3-butadien-1,4-ylene group,
    D denotes a C1-4-alkylene group,
    or, if D is bound to a carbon atom of the group E, it may also denote a bond,
    or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl group,
    E denotes a di-(C1-4-alkyl)-amino group wherein the alkyl moieties may be identical or different,
    an N—(C1-4-alkyl)-N—(C2-4-alkyl)-amino group wherein the C2-4-alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, whilst
    R5 denotes a hydroxy, C1-3-alkoxy or di-(C1-3-alkyl)-amino group,
    a pyrrolidino, piperidino or morpholino group,
    a di-(C2-4-alkyl)-amino group wherein the two C2-4-alkyl moieties in each case are substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, wherein the substitutents may be identical or different and R5 is as hereinbefore defined,
    an C1-4-alkylamino group substituted at the nitrogen atom by a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, 1-(C1-2-alkyl)-pyrrolidin-3-yl, 1-(C1-2-alkyl)-piperidin-3-yl, 1-(C1-2-alkyl)-piperidin-4-yl, 1-(tetrahydrofuran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-3-yl)-piperidin-4-yl or 1-(tetrahydropyran-4-yl)-piperidin-4-yl group,
    a C3-5-cycloalkylamino or C3-5-cycloalkyl-C1-3-alkylamino group wherein in each case the nitrogen atom is substituted by a further C1-3-alkyl group,
    a 5- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups which may be substituted either at a cyclic carbon atom or at one or the methyl groups by the group R5, where R5 is as hereinbefore defined, or
    a piperidino group substituted by a tetrahydrofuranyl, tetrahydropyranyl or tetrahydrofuranylmethyl group,
    a piperidino group optionally substituted by 1 or 2 methyl groups wherein the methylene group is replaced in the 4 position by an oxygen or sulfur atom, by sulfinyl or sulfonyl group or by an imino group substituted by the group R6, whilst
    R6 denotes a C1-3-alkyl, 2-methoxy-ethyl, 3-methoxy-propyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-3-alkyl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, C1-3-alkylcarbonyl, C1-3-alkylsulfonyl, aminocarbonyl, C1-3-alkylaminocarbonyl or di-(C1-3-alkyl)-aminocarbonyl group,
    or D together with E denotes a hydrogen atom,
    a C1-3-alkyl group,
    an aryl or C1-4-alkylcarbonyl group or
    a C1-4-alkoxycarbonyl group,
    Rc denotes a C4-7-cycloalkoxy or C3-7-cycloalkyl-C1-4-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C1-3-alkyl or C1-3-alkoxy group,
    a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuranylmethoxy group,
    an C2-4-alkoxy group substituted in β-, γ-, or δ-position with regard to the oxygen atom by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,
    a 3-pyrrolidinyloxy, 2-pyrrolidinyl-C1-3-alkyloxy, 3-pyrrolidinyl-C1-3-alkyloxy, 3-piperidinyloxy, 4-piperidinyloxy, 2-piperidinyl-C1-3-alkyloxy, 3-piperidinyl-C1-3-alkyloxy, 4-piperidinyl-C1-3-alkyloxy, 3-hexahydro-azepinyloxy, 4-hexahydro-azepinyloxy, 2-hexahydro-azepinyl-C1-3-alkyloxy, 3-hexahydro-azepinyl-C1-3-alkyloxy or 4-hexahydro-azepinyl-C1-3-alkyloxy group wherein in each case the cyclic nitrogen atom is substituted by a methyl or ethyl group, whilst
    by the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which may be mono-, di- or trisubstituted by R8, wherein the substitutents may be identical or different and
    R8 denotes a fluorine, chlorine, bromine or iodine atom, a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group,
    the tautomers, stereoisomers and salts thereof.
  4. 4. Bicyclic heterocycles of general formula I according to claim 1, wherein
    Ra denotes a hydrogen atom,
    Rb denotes a phenyl, benzyl or 1-phenylethyl group, whilst the phenyl nucleus is substituted in each case by the radicals R1 and R2, whilst
    R1 and R2, which may be identical or different, each denotes a hydrogen, fluorine, chlorine or bromine atom,
    X denotes a nitrogen atom,
    A denotes an imino group,
    B denotes a carbonyl group,
    C denotes a 1,2-vinylene, ethinylene or 1,3-butadien-1,4-ylene group,
    D denotes an C1-3-alkylene group,
    E denotes a Di-(C1-4-alkyl)-amino group, wherein the alkyl moieties may be identical or different,
    a methylamino or ethylamino group each substituted at the nitrogen atom by a 2-methoxyethyl, 1-methoxy-2-propyl, 2-methoxypropyl, 3-methoxypropyl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl, tetrahydrofuran-2-ylmethyl, 1-methylpiperidin-4-yl, 1-ethyl-piperidin-4-yl, 1-(tetrahydrofuran-3-yl)-piperidin-4-yl, cyclopropyl or cyclopropylmethyl group,
    a Bis(2-methoxyethyl)amino group,
    a pyrrolidino, piperidino or morpholino group each optionally substituted by one or two methyl groups,
    a piperazino group substituted in 4-position by a methyl, ethyl, cyclopropyl, cyclopropylmethyl, 2-methoxy-ethyl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl or tetrahydrofuran-2-ylmethyl group,
    a thiomorpholino, S-oxidothiomorpholino or S,S-dioxidothiomorpholino group,
    a 2-(methoxymethyl)pyrrolidino, 2-(ethoxymethyl)pyrrolidino, 4-hydroxypiperidino, 4-methoxypiperidino, 4-ethoxypiperidino, 4-(tetrahydrofuran-3-yl)piperidino or 4-morpholinopiperidino group
    or D together with E denote a hydrogen atom, a methyl, phenyl, methoxycarbonyl or ethoxycarbonyl group and
    Rc denotes a cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy or cyclohexylmethoxy group,
    a cyclobutyloxy, cyclopentyloxy or cyclohexyloxy group,
    a tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuran-2-ylmethoxy group,
    a straight chained C2-4-alkoxy group terminally substituted by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,
    a 1-methyl-piperidin-4-yloxy or 1-ethyl-piperidin-4-yloxy group,
    a (1-methyl-piperidin-4-yl)-C1-3-alkyloxy or (1-ethyl-piperidin-4-yl)-C1-3-alkyloxy group,
    the tautomers, stereoisomers and salts thereof.
  5. 5. Bicyclic heterocycles of general formula I according to claim 1, wherein
    Ra denotes a hydrogen atom,
    Rb denotes a 1-phenylethyl group or a phenyl group wherein the phenyl nucleus is substituted by the radicals R1 and R2, whilst
    R1 and R2, which may be identical or different, each denote a hydrogen, fluorine, chlorine or bromine atom,
    X denotes a nitrogen atom,
    A denotes an imino group,
    B denotes a carbonyl group,
    C denotes a 1,2-vinylene, ethinylene or 1,3-butadien-1,4-ylene group,
    D denotes a methylene group,
    E denotes a dimethylamino, diethylamino, Bis(2-methoxyethyl)amino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, N-methyl-N-cyclopropylamino, N-methyl-N-cyclopropylmethyl-amino, N-methyl-N-(1-methoxy-2-propyl)amino, N-methyl-N-(2-methoxypropyl)amino, N-methyl-N-(3-methoxypropyl)amino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino or N-methyl-N-(1-methylpiperidin-4-yl)amino group,
    a pyrrolidino, piperidino or morpholino group each optionally substituted by one or two methyl groups,
    a piperazino group substituted in 4-position by a methyl, ethyl, cyclopropylmethyl or 2-methoxyethyl group,
    a S-oxidothiomorpholino group,
    a 2-(methoxymethyl)pyrrolidino, 4-hydroxypiperidino or 4-methoxypiperidino group
    or D together with E denote a hydrogen atom, a methyl, phenyl or ethoxycarbonyl group, and
    Rc denotes a cyclopropylmethoxy, cyclobutyloxy or cyclopentyloxy group,
    a tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuran-2-ylmethoxy group,
    a straight chained C2-4-alkoxy group terminally substituted by an azetidin-1-yl or 4-methylhomopiperazino group,
    a 1-methyl-piperidin-4-yloxy group or
    a (1-methylpiperidin-4-yl)-C1-3-alkyloxy group,
    the tautomers, stereoisomers and salts thereof.
  6. 6. The following compounds of general formula I according to claim 1:
    (a) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline,
    (b) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline and
    (c) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    as well as the salts thereof.
  7. 7. Physiologically acceptable salts of the compounds according to at least one of claims 1 to 6 with inorganic or organic acids or bases.
  8. 8. Pharmaceutical compositions containing a compound according to at least one of claims 1 to 6 or a physiologically acceptable salt according to claim 7 optionally together with one or more inert carriers and/or diluents.
  9. 9. Use of a compound according to at least one of claims 1 to 7 for preparing a pharmaceutical composition which is suitable for treating benign or malignant tumors, for preventing and treating diseases of the airways and lungs and for treating diseases of the gastrointestinal tract and the bile duct and gall bladder.
  10. 10. Process for preparing a pharmaceutical composition according to claim 8, characterized in that a compound according to at least one of claims 1 to 7 is incorporated in one or more inert carriers and/or diluents by a non-chemical method.
  11. 11. Process for preparing the compounds of general formula I according to claims 1 to 7, characterized in that
    a) a compound of general formula
    Figure US20070185091A1-20070809-C00006
    wherein
    Ra to Rc, A and X are defined as in claims 1 to 6, is reacted with a compound of general formula

    Z1-B-C-D-E  (III)
    wherein
    B to E are defined as in claims 1 to 6 and
    Z1 denotes a leaving group, or
    b) in order to prepare compounds of general formula I wherein the group E is linked to the group D via a nitrogen atom, a compound of general formula
    Figure US20070185091A1-20070809-C00007
    wherein
    Ra to Rc, A to D and X are defined as in claims 1 to 6 and
    Z2 denotes a leaving group, is reacted with a compound of general formula

    H-E′  (V)
    wherein
    E′ denotes one of the groups mentioned for E in claims 1 to 6 which is linked to the group D via a nitrogen atom, and
    if desired a compound of general formula I thus obtained which contains an amino, alkylamino or imino group is converted by acylation or sulfonylation into a corresponding acyl or sulfonyl compound of general formula I and/or
    a compound of general formula I thus obtained which contains an amino, alkylamino or imino group is converted by alkylation or reductive alkylation into a corresponding alkyl compound of general formula I and/or
    a compound of general formula I thus obtained which contains a carboxy or hydroxyphosphoryl group is converted by esterification into a corresponding ester of general formula I and/or
    a compound of general formula I thus obtained which contains a carboxy or ester group is converted by reaction with a corresponding amine into a corresponding amide of general formula I and/or
    if necessary any protecting group used during the above reactions is cleaved again and/or
    if desired a compound of general formula I thus obtained is resolved into its stereoisomers and/or
    a compound of general formula I thus obtained is converted into the salts thereof, more particularly, for pharmaceutical use, into the physiologically acceptable salts thereof.
  12. 13. Bicyclic heterocycles of general formula
    Figure US20070185091A1-20070809-C00008
    wherein
    Ra denotes a hydrogen atom or a C1-4-alkyl group,
    Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R1 to R3, whilst
    R1 and R2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom,
    a C1-4-alkyl, hydroxy, C1-4-alkoxy, C3-6-cycloalkyl, C4-6-cycloalkoxy, C2-5-alkenyl or C2-5-alkynyl group,
    an aryl, aryloxy, arylmethyl or arylmethoxy group,
    a C3-5-alkenyloxy or C3-5-alkynyloxy group, whilst the unsaturated moiety may not be linked to the oxygen atom,
    a C1-4-alkylsulfenyl, C1-4-alkylsulfinyl, C1-4-alkylsulfonyl, C1-4-alkylsulfonyloxy, trifluoromethylsulfenyl, trifluoromethylsulfinyl or trifluoromethylsulfonyl group,
    a methyl or methoxy group substituted by 1 to 3 fluorine atoms, an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms,
    a cyano or nitro group or an amino group optionally substituted by one or two C1-4-alkyl groups, wherein the substitutents may be identical or different, or
    R1 together with R2, if they are bound to adjacent carbon atoms, denote a —CH═CH—CH═CH, —CH═CH—NH or —CH═N—NH group and
    R3 denotes a hydrogen, fluorine, chlorine or bromine atom,
    a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group,
    X denotes a methine group substituted by a cyano group,
    A denotes an imino group optionally substituted by a C1-4-alkyl group,
    B denotes a carbonyl or sulfonyl group,
    C denotes a 1,3-allenylene, 1,1- or 1,2-vinylene group which may be substituted in each case by one or two methyl groups or by a trifluoromethyl group,
    an ethynylene group or
    a 1,3-butadien-1,4-ylene group optionally substituted by 1 to 4 methyl groups or by a trifluoromethyl group,
    D denotes an alkylene, —CO-alkylene or —SO2-alkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, whilst the linking of the —CO-alkylene or —SO2-alkylene group to the adjacent group C in each case must take place via the carbonyl or sulfonyl group,
    a —CO—O-alkylene, —CO—NR4-alkylene or —SO2—NR4-alkylene group wherein the alkylene moiety in each case contains 1 to 8 carbon atoms, whilst the linking to the adjacent group C in each case must take place via the carbonyl or sulfonyl group, wherein
    R4 denotes a hydrogen atom or a C1-4-alkyl group,
    or, if D is bound to a carbon atom of the group E, it may also denote a bond
    or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulfonyl group,
    E denotes an amino, C1-4-alkylamino or di-(C1-4-alkyl)-amino group wherein the alkyl moieties may be identical or different,
    a C2-4-alkylamino group wherein the alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, whilst
    R5 denotes a hydroxy, C1-4-alkoxy, amino, C1-4-alkylamino or di-(C1-4-alkyl)-amino group,
    a 4- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups or
    a 6- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups wherein in each case a methylene group in position 4 is replaced by an oxygen or sulfur atom, by a sulfinyl, sulfonyl, imino or N—(C1-4-alkyl)-imino group,
    an N—(C1-4-alkyl)-N—(C2-4-alkyl)-amino group wherein the C2-4-alkyl moiety is substituted in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, whilst R5 is as hereinbefore defined,
    a di-(C2-4-alkyl)-amino group wherein the two C2-4-alkyl moieties are substituted in each case in β-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, whilst the substitutents may be identical or different and R5 is as hereinbefore defined,
    a C3-7-cycloalkylamino or C3-7-cycloalkyl-C1-3-alkylamino group wherein in each case the nitrogen atom may be substituted by a further C1-4-alkyl group,
    an amino or C1-4-alkylamino group wherein in each case the nitrogen atom is substituted by a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, 1-(tetrahydrofuran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-4-yl)-piperidin-4-yl, 3-pyrrolidinyl, 3-piperidinyl, 4-piperidinyl, 3-hexahydro-azepinyl or 4-hexahydro-azepinyl group optionally substituted by 1 to 3 C1-4-alkyl groups,
    a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 C1-2-alkyl groups, which may be substituted by the group R5 either at a cyclic carbon atom or at one of the alkyl groups, whilst R5 is as hereinbefore defined,
    a piperidino group substituted by a tetrahydrofuranyl, tetrahydropyranyl or tetrahydrofuranylmethyl group,
    a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 C1-2-alkyl groups wherein a methylene group in each case is replaced in the 4 position by an oxygen or sulfur atom, by an imino group substituted by the group R6, or by a sulfinyl or sulfonyl group, whilst
    R6 denotes a hydrogen atom, a C1-4-alkyl, 2-methoxy-ethyl, 3-methoxy-propyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, formyl, C1-4-alkylcarbonyl, C1-4-alkylsulfonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group,
    an imidazolyl group optionally substituted by 1 to 3 methyl groups,
    a C5-7-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulfur atom, by an imino group substituted by the group R6, by a sulfinyl or sulfonyl group, whilst R6 is as hereinbefore defined,
    or D together with E denotes a hydrogen, fluorine or chlorine atom,
    a C1-4-alkyl group optionally substituted by 1 to 5 fluorine atoms,
    a C3-6-cycloalkyl group,
    an aryl, heteroaryl, C1-4-alkylcarbonyl or arylcarbonyl group,
    a carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group or
    a carbonyl which is substituted by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group may be replaced in the 4 position by an oxygen or sulfur atom, by an imino group substituted by the group R6, by a sulfinyl or sulfonyl group, whilst R6 is as hereinbefore defined, and
    Rc denotes a C4-7-cycloalkoxy or C3-7-cycloalkyl-C1-6-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C1-3-alkyl, hydroxy, C1-4-alkoxy, amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, pyrrolidino, piperidino, morpholino, piperazino, N—(C1-12-alkyl)-piperazino, hydroxy-C1-2-alkyl, C1-4-alkoxy-C1-2-alkyl, amino-C1-12-alkyl, C1-4-alkylamino-C1-2-alkyl, di-(C1-4-alkyl)-amino-C1-2-alkyl, pyrrolidino-C1-2-alkyl, piperidino-C1-2-alkyl, morpholino-C1-2-alkyl, piperazino-C1-2-alkyl or N—(C1-2-alkyl)-piperazino-C1-2-alkyl group, whilst the abovementioned monosubstituted cycloalkyl moieties may additionally be substituted by a C1-3-alkyl group,
    a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuranylmethoxy group,
    an C2-4-alkoxy group substituted in Dβ-, γ-, or δ-position with regard to the oxygen atom by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,
    a 3-pyrrolidinyloxy, 2-pyrrolidinyl-C1-4-alkyloxy, 3-pyrrolidinyl-C1-4-alkyloxy, 3-piperidinyloxy, 4-piperidinyloxy, 2-piperidinyl-C1-4-alkyloxy, 3-piperidinyl-C1-4-alkyloxy, 4-piperidinyl-C1-4-alkyloxy, 3-hexahydro-azepinyloxy, 4-hexahydro-azepinyloxy, 2-hexahydro-azepinyl-C1-4-alkyloxy, 3-He-xahydro-azepinyl-C1-4-alkyloxy or 4-hexahydro-azepinyl-C1-4-alkyloxy group wherein in each case the cyclic nitrogen atom is substituted by the group R6, where R6 is as hereinbefore defined, whilst
    by the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which in each case may be monosubstituted by R7, mono-, di- or trisubstituted by R8 or monosubstituted by R7 and additionally mono- or disubstituted by R8, wherein the substitutents may be identical or different and
    R7 denotes a cyano, carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl, di-(C1-4-alkyl)-aminocarbonyl, C1-4-alkylsulfenyl, C1-4-alkylsulfinyl, C1-4-alkylsulfonyl, hydroxy, C1-4-alkylsulfonyloxy, trifluoromethyloxy, nitro, amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, C1-4-alkyl-carbonylamino, N—(C1-4-alkyl)-C1-4-alkylcarbonylamino, C1-4-alkylsulfonylamino, N—(C1-4-alkyl)-C1-4-alkylsulfonylamino, aminosulfonyl, C1-4-alkylaminosulfonyl or di-(C1-4-alkyl)-aminosulfonyl group or a carbonyl group which is substituted by a 5- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulfur atom, by a sulfinyl, sulfonyl, imino or N—(C1-4-alkyl)-imino group, and
    R8 denotes a fluorine, chlorine, bromine or iodine atom, a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group or
    two groups R8, if they are bound to adjacent carbon atoms, together denote a C3-5-alkylene, methylenedioxy or 1,3-butadien-1,4-ylene group,
    and the heteroaryl groups mentioned in the definition of the abovementioned groups include a 5-membered heteroaromatic group which contains an imino group, an oxygen or sulfur atom or an imino group, an oxygen or sulfur atom and one or two nitrogen atoms, or
    a 6-membered heteroaromatic group which contains one, two or three nitrogen atoms,
    whilst the abovementioned 5-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups and the abovementioned 6-membered heteroaromatic groups may be substituted in each case by 1 or 2 methyl or ethyl groups or by a fluorine, chlorine, bromine or iodine atom or by a trifluoromethyl, hydroxy, methoxy or ethoxy group,
    the tautomers, stereoisomers and salts thereof.
  13. 14. Bicyclic heterocycles of general formula I according to claim 13, wherein
    Ra denotes a hydrogen atom,
    Rb denotes a phenyl, benzyl or 1-phenylethyl group wherein the phenyl nucleus is substituted in each case by the groups R1 to R3, whilst
    R1 and R2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom,
    a C1-4-alkyl, hydroxy, C1-4-alkoxy, C3-6-cycloalkyl, C4-6-cycloalkoxy, C2-5-alkenyl or C2-5-alkynyl group,
    an aryl, aryloxy, arylmethyl or arylmethoxy group,
    a methyl or methoxy group substituted by 1 to 3 fluorine atoms,
    a cyano or nitro group and
    R3 denotes a hydrogen, fluorine, chlorine or bromine atom,
    a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group,
    X denotes a methine group substituted by a cyano group,
    A denotes an imino group,
    B denotes a carbonyl or sulfonyl group,
    C denotes a 1,3-allenylene, 1,1- or 1,2-vinylene group,
    an ethynylene or 1,3-butadien-1,4-ylene group,
    D denotes an alkylene, —CO-alkylene or —SO2-alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms and additionally 1 to 4 hydrogen atoms in the alkylene moiety may be replaced by fluorine atoms, whilst the linking of the —CO-alkylene or —SO2-alkylene group to the adjacent group C in each case must take place via the carbonyl or sulfonyl group,
    a —CO—O-alkylene, —CO—NR4-alkylene or —SO2—NR4-alkylene group wherein the alkylene moiety in each case contains 1 to 4 carbon atoms, whilst the linking to the adjacent group C in each case must take place via the carbonyl or sulfonyl group, wherein
    R4 denotes a hydrogen atom or a C1-4-alkyl group,
    or, if D is bound to a carbon atom of the group E, it may also denote a bond,
    or, if D is bound to a nitrogen atom of the group E, it may also denote a carbonyl or sulfonyl group,
    E denotes a di-(C1-4-alkyl)-amino group wherein the alkyl moieties may be identical or different,
    an N—(C1-4-alkyl)-N—(C2-4-alkyl)-amino group wherein the C2-4-alkyl moiety is substituted in Dβ-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, where
    R5 denotes a hydroxy, C1-4-alkoxy or di-(C1-4-alkyl)-amino group,
    a 4- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups or
    a 6- to 7-membered alkyleneimino group optionally substituted by one or two methyl groups wherein in each case a methylene group in position 4 is replaced by an oxygen or sulfur atom, or by a sulfinyl, sulfonyl or N—(C1-4-alkyl)-imino group,
    a di-(C2-4-alkyl)-amino group wherein the two C2-4-alkyl moieties in each case are substituted in Dβ-, γ-, or δ-position with regard to the nitrogen atom of the amino group by the group R5, wherein the substitutents may be identical or different and R5 is as hereinbefore defined,
    a C3-7-cycloalkylamino or C3-7-cycloalkyl-C1-3-alkylamino group wherein in each case the nitrogen atom is substituted by a further C1-4-alkyl group,
    a C1-4-alkylamino group wherein the nitrogen atom is substituted by a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, 1-(tetrahydrofuran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-3-yl)-piperidin-4-yl, 1-(tetrahydropyran-4-yl)-piperidin-4-yl, N—(C1-12-alkyl)-3-pyrrolidinyl, N—(C1-2-alkyl)-3-piperidinyl, N—(C1-2-alkyl)-4-piperidinyl, N—(C1-2-alkyl)-3-hexahydro-azepinyl or N—(C1-2-alkyl)-4-hexahydro-azepinyl group,
    an 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups, which may be substituted either at a cyclic carbon atom or at one of the methyl groups by the group R5, where R5 is as hereinbefore defined,
    a piperidino group substituted by a tetrahydrofuranyl, tetrahydropyranyl or tetrahydrofuranylmethyl group,
    a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups wherein in each case a methylene group is replaced in the 4 position by an oxygen or sulfur atom, by an imino group substituted by the group R6, by a sulfinyl or sulfonyl group, whilst
    R6 denotes a C1-4-alkyl, 2-methoxy-ethyl, 3-methoxy-propyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrofuranylmethyl, formyl, C1-4-alkylcarbonyl, C1-4-alkylsulfonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group,
    a C5-7-cycloalkyl group wherein a methylene group is replaced by an oxygen or sulfur atom, by an imino group substituted by the group R6, or by a sulfinyl or sulfonyl group, where R6 is as hereinbefore defined,
    or D together with E denotes a hydrogen, fluorine or chlorine atom,
    a C1-4-alkyl group optionally substituted by 1 to 5 fluorine atoms,
    a C3-6-cycloalkyl group,
    an aryl, C1-4-alkylcarbonyl or arylcarbonyl group,
    a carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl or di-(C1-4-alkyl)-aminocarbonyl group or
    a carbonyl group which is substituted by a 4- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group in the 4 position may be replaced by an oxygen or sulfur atom, by an imino group substituted by the group R6, or by a sulfinyl or sulfonyl group, where R6 is as hereinbefore defined, and
    Rc denotes a C4-7-cycloalkoxy or C3-7-cycloalkyl-C1-6-alkoxy group wherein the cycloalkyl moiety in each case may be substituted by a C1-3-alkyl, hydroxy, C1-4-alkoxy, di-(C1-4-alkyl)-amino, pyrrolidino, piperidino, morpholino, N—(C1-2-alkyl)-piperazino, hydroxy-C1-2-alkyl, C1-4-alkoxy-C1-2-alkyl, di-(C1-4-alkyl)-amino-C1-12-alkyl, pyrrolidino-C1-2-alkyl, piperidino-C1-2-alkyl, morpholino-C1-2-alkyl or N—(C1-2-alkyl)-piperazino-C1-2-alkyl group, whilst the abovementioned monosubstituted cycloalkyl moieties may additionally be substituted by a C1-3-alkyl group,
    a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy or tetrahydrofuranylmethoxy group,
    an C2-4-alkoxy group substituted in Dβ-, γ-, or δ-position with regard to the oxygen atom by an azetidin-1-yl, 4-methyl-homopiperazino or 4-ethyl-homopiperazino group,
    a 3-pyrrolidinyloxy, 2-pyrrolidinyl-C1-4-alkyloxy, 3-pyrrolidinyl-C1-4-alkyloxy, 3-piperidinyloxy, 4-piperidinyloxy, 2-piperidinyl-C1-4-alkyloxy, 3-piperidinyl-C1-4-alkyloxy, 4-piperidinyl-C1-4-alkyloxy, 3-hexahydro-azepinyloxy, 4-hexahydro-azepinyloxy, 2-hexahydro-azepinyl-C1-4-alkyloxy, 3-hexahydro-azepinyl-C1-4-alkyloxy or 4-hexahydro-azepinyl-C1-4-alkyloxy group wherein in each case the cyclic nitrogen atom is substituted by the group R6, where R6 is as hereinbefore defined, whilst by the aryl moieties mentioned in the definition of the abovementioned groups is meant a phenyl group which may in each case be monosubstituted by R7, mono-, di- or trisubstituted by R8 or monosubstituted by R7 and additionally mono- or disubstituted by R8, wherein the substitutents may be identical or different and
    R7 denotes a cyano, carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-4-alkylaminocarbonyl, di-(C1-4-alkyl)-aminocarbonyl, C1-4-alkylsulfenyl, C1-4-alkylsulfinyl, C1-4-alkylsulfonyl, hydroxy, C1-4-alkylsulfonyloxy, trifluoromethyloxy, nitro, amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, C1-4-alkyl-carbonylamino, N—(C1-4-alkyl)-C1-4-alkylcarbonylamino, C1-4-alkylsulfonylamino, N—(C1-4-alkyl)-C1-4-alkylsulfonylamino, aminosulfonyl, C1-4-alkylaminosulfonyl or di-(C1-4-alkyl)-aminosulfonyl group or a carbonyl group which is substituted by a 5- to 7-membered alkyleneimino group, whilst in the abovementioned 6- to 7-membered alkyleneimino groups in each case a methylene group may be replaced in the 4 position by an oxygen or sulfur atom, by a sulfinyl, sulfonyl, imino or N—(C1-4-alkyl)-imino group, and
    R8 denotes a fluorine, chlorine, bromine or iodine atom, a C1-4-alkyl, trifluoromethyl or C1-4-alkoxy group or
    two groups R8, if they are bound to adjacent carbon atoms, together denote a C3-5-alkylene, methylenedioxy or 1,3-butadien-1,4-ylene group,
    the tautomers, stereoisomers and salts thereof.
  14. 15. The following compounds of general formula I according to claim 13:
    (a) 4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(1-methylpiperidin-4-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline,
    (b) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline and
    (c) 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline
    as well as the salts thereof.
  15. 16. Physiologically acceptable salts of the compounds according to claim 13 with inorganic or organic acids or bases.
  16. 17. Pharmaceutical compositions comprising a compound according to claim 13, optionally together with one or more inert carriers and/or diluents.
  17. 18. A method for treating benign or malignant tumors, for preventing and treating diseases of the airways and lungs and for treating diseases of the gastrointestinal tract and the bile duct and gall bladder in a warm-blooded animal which comprises administering to said animal a therapeutically effective amount of a compound according to claim 13.
  18. 19. Process for preparing the compounds of general formula I according to claim 13 characterized in that
    a) a compound of general formula
    Figure US20070185091A1-20070809-C00009
    wherein
    Ra to Rc, A and X are defined as in claim 13, is reacted with a compound of general formula

    Z1-B-C-D-E  (III)
    wherein
    B to E are defined as in claim 13 and
    Z1 denotes a leaving group, or
    b) in order to prepare compounds of general formula I wherein the group E is linked to the group D via a nitrogen atom, a compound of general formula
    Figure US20070185091A1-20070809-C00010
    wherein
    Ra to Rc, A to D and X are defined as in claim 13 and
    Z2 denotes a leaving group, is reacted with a compound of general formula

    H-E′  (V)
    wherein
    E′ denotes one of the groups mentioned for E in claim 13 which is linked to the group D via a nitrogen atom, and
    if desired a compound of general formula I thus obtained which contains an amino, alkylamino or imino group is converted by acylation or sulfonylation into a corresponding acyl or sulfonyl compound of general formula I and/or
    a compound of general formula I thus obtained which contains an amino, alkylamino or imino group is converted by alkylation or reductive alkylation into a corresponding alkyl compound of general formula I and/or
    a compound of general formula I thus obtained which contains a carboxy or hydroxyphosphoryl group is converted by esterification into a corresponding ester of general formula I and/or
    a compound of general formula I thus obtained which contains a carboxy or ester group is converted by reaction with a corresponding amine into a corresponding amide of general formula I and/or
    if necessary any protecting group used during the above reactions is cleaved again and/or
    if desired a compound of general formula I thus obtained is resolved into its stereoisomers and/or
    a compound of general formula I thus obtained is converted into the salts thereof, more particularly, for pharmaceutical use, into the physiologically acceptable salts thereof.
US11734350 1999-06-21 2007-04-12 Bicyclic Heterocycles, Pharmaceutical Compositions Containing These Compounds, Their Use and Processes for Preparing Them Abandoned US20070185091A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE19928281.1 1999-06-21
DE1999128281 DE19928281A1 (en) 1999-06-21 1999-06-21 Arylamino and aralkylamino substituted quinoline and quinazoline derivatives, useful for the treatment of e.g. tumors, pulmonary, respiratory and gastrointestinal disorders and psoriasis
US14664499 true 1999-07-30 1999-07-30
DE10023085.7 2000-05-11
DE2000123085 DE10023085A1 (en) 2000-05-11 2000-05-11 Arylamino and aralkylamino substituted quinoline and quinazoline derivatives, useful for the treatment of e.g. tumors, pulmonary, respiratory and gastrointestinal disorders and psoriasis
PCT/EP2000/005547 WO2000078735A1 (en) 1999-06-21 2000-06-16 Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
US10016280 US7220750B2 (en) 1999-06-21 2001-12-10 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US11734350 US20070185091A1 (en) 1999-06-21 2007-04-12 Bicyclic Heterocycles, Pharmaceutical Compositions Containing These Compounds, Their Use and Processes for Preparing Them

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11734350 US20070185091A1 (en) 1999-06-21 2007-04-12 Bicyclic Heterocycles, Pharmaceutical Compositions Containing These Compounds, Their Use and Processes for Preparing Them
US12624875 US20100069414A1 (en) 1999-06-21 2009-11-24 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US13603476 US8722694B2 (en) 1999-06-21 2012-09-05 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10016280 Continuation US7220750B2 (en) 1999-06-21 2001-12-10 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12624875 Continuation US20100069414A1 (en) 1999-06-21 2009-11-24 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Publications (1)

Publication Number Publication Date
US20070185091A1 true true US20070185091A1 (en) 2007-08-09

Family

ID=27213849

Family Applications (4)

Application Number Title Priority Date Filing Date
US10016280 Active 2021-04-08 US7220750B2 (en) 1999-06-21 2001-12-10 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US11734350 Abandoned US20070185091A1 (en) 1999-06-21 2007-04-12 Bicyclic Heterocycles, Pharmaceutical Compositions Containing These Compounds, Their Use and Processes for Preparing Them
US12624875 Abandoned US20100069414A1 (en) 1999-06-21 2009-11-24 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US13603476 Active US8722694B2 (en) 1999-06-21 2012-09-05 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10016280 Active 2021-04-08 US7220750B2 (en) 1999-06-21 2001-12-10 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12624875 Abandoned US20100069414A1 (en) 1999-06-21 2009-11-24 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US13603476 Active US8722694B2 (en) 1999-06-21 2012-09-05 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Country Status (8)

Country Link
US (4) US7220750B2 (en)
EP (2) EP1194418A1 (en)
JP (1) JP3686610B2 (en)
CN (1) CN1166645C (en)
CA (1) CA2375259C (en)
DK (1) DK1731511T3 (en)
ES (1) ES2552813T3 (en)
WO (1) WO2000078735A1 (en)

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138215A1 (en) * 2002-11-21 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040138214A1 (en) * 2002-11-08 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040166125A1 (en) * 2002-08-22 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US20050187227A1 (en) * 2004-02-23 2005-08-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition
US20050234108A1 (en) * 2004-02-18 2005-10-20 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20050261352A1 (en) * 2004-05-10 2005-11-24 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US20060004074A1 (en) * 2004-06-24 2006-01-05 Boehringer Ingelheim International Gmbh New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US20060058323A1 (en) * 2004-09-11 2006-03-16 Boehringer Ingelheim International Gmbh New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060079541A1 (en) * 2004-09-14 2006-04-13 Boehringer Ingelheim International Gmbh 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060142310A1 (en) * 2004-11-05 2006-06-29 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US20060247226A1 (en) * 2001-02-24 2006-11-02 Frank Himmelsbach Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20070027170A1 (en) * 2003-10-17 2007-02-01 Rainer Soyka Process for preparing amino crotonyl compounds
US20070027168A1 (en) * 2005-07-30 2007-02-01 Waldemar Pfrengle 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US20070259900A1 (en) * 2006-05-04 2007-11-08 Peter Sieger Polymorphs
US20070281940A1 (en) * 2006-05-04 2007-12-06 Klaus Dugi Uses of dpp-iv inhibitors
US20080103161A1 (en) * 2002-04-19 2008-05-01 Frank Himmelsbach Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US20080107731A1 (en) * 2006-05-04 2008-05-08 Anja Kohlrausch Dpp iv inhibitor formulations
US20080254040A1 (en) * 2003-04-29 2008-10-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20080255159A1 (en) * 2002-08-21 2008-10-16 Boehringer Ingelheim Pharma Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20090088569A1 (en) * 2004-04-10 2009-04-02 Matthias Eckhardt 2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation, and their use as pharmaceutical compositions
US7550455B2 (en) 2003-11-27 2009-06-23 Boehringer Ingelheim International Gmbh 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US20090306378A1 (en) * 2006-01-26 2009-12-10 Juergen Schroeder Process for preparing aminocrotonylamino-substituted quinazoline derivatives
US20090306044A1 (en) * 2005-11-11 2009-12-10 Flavio Solca Quinazoline derivatives for the treatment of cancer diseases
US20090306101A1 (en) * 2005-11-11 2009-12-10 Flavio Solca Combination treatment of cancer comprising egfr/her2 inhibitors
US20090318480A1 (en) * 2006-09-18 2009-12-24 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
US20100010023A1 (en) * 2000-12-20 2010-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US20100069414A1 (en) * 1999-06-21 2010-03-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20100144639A1 (en) * 2002-05-11 2010-06-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph) / prostatic hypertrophy
US20110142929A1 (en) * 2008-06-06 2011-06-16 Boehringer Ingelheim International Gmbh Solid pharmaceutical formulations comprising bibw 2992
US8071583B2 (en) 2006-08-08 2011-12-06 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US9556191B2 (en) 2013-04-28 2017-01-31 Sunshine Lake Pharma Co., Ltd. Aminoquinazoline derivatives and their salts and methods of use thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042060A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for their preparation
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
DE10063435A1 (en) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate medicaments containing these compounds, their use and processes for their preparation
WO2003000705A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
DE10204462A1 (en) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
DK1487806T3 (en) * 2002-03-28 2010-09-20 Astrazeneca Ab 4-anilino-quinazoline derivatives as antiproliferative agents
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10217689A1 (en) * 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10230751A1 (en) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pharmaceutical compositions based on novel anticholinergics and EGFR kinase inhibitors
US20040048887A1 (en) * 2002-07-09 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
US7223749B2 (en) * 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2005012290A1 (en) * 2003-07-29 2005-02-10 Astrazeneca Ab Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
CA2541100A1 (en) * 2003-09-16 2005-03-24 Astrazenca Ab Quinazoline derivatives
RU2378268C2 (en) * 2003-09-16 2010-01-10 Астразенека Аб Quinoline derivatives as tyrosine kinase inhibitors
ES2281007T3 (en) * 2003-09-19 2007-09-16 Astrazeneca Ab Quinazoline derivatives.
DK1667992T3 (en) 2003-09-19 2007-04-30 Astrazeneca Ab quinazoline
KR20060100388A (en) * 2003-09-25 2006-09-20 아스트라제네카 아베 Quinazoline derivatives
DK2213661T3 (en) * 2003-09-26 2011-09-19 Exelixis Inc C-met modulators and methods of use
DE10345875A1 (en) * 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclic heterocycles medicaments containing these compounds, their Vewendung and processes for their preparation
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US20050203088A1 (en) * 2004-01-09 2005-09-15 Boehringer Ingelheim International Gmbh Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors
JP5032851B2 (en) 2004-02-03 2012-09-26 アストラゼネカ アクチボラグ Quinazoline derivatives
CA2565812C (en) * 2004-05-06 2012-03-13 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US20060142373A1 (en) 2004-12-24 2006-06-29 Boehringer Ingelheim International Gmbh Medicaments for the Treatment or Prevention of Fibrotic Diseases
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc Compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006081741A1 (en) * 2005-02-05 2006-08-10 Piaoyang Sun Quinazoline compounds or their medical salts and preparation and medical usage thereof
KR20070107151A (en) 2005-02-26 2007-11-06 아스트라제네카 아베 Quinazoline derivatives as tyrosine kinase inhibitors
KR100832594B1 (en) * 2005-11-08 2008-05-27 한미약품 주식회사 Quinazoline derivatives as an multiplex inhibitor and method for the preparation thereof
EP1921070A1 (en) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
US7998949B2 (en) * 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8497369B2 (en) * 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
WO2009138781A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
JP5539351B2 (en) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング A medicament containing a cyclohexyl-substituted heterocycle, these compounds, and methods for producing them
JP5781934B2 (en) * 2008-11-10 2015-09-24 ナショナル ヘルス リサーチ インスティテューツ Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
CA2995880A1 (en) 2009-01-16 2010-07-22 Exelixis, Inc. Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
EP2875020B1 (en) 2012-07-19 2017-09-06 Boehringer Ingelheim International GmbH Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
CN103804308A (en) * 2012-11-06 2014-05-21 天津药物研究院 7-substituted cyclohexyl quinazoline derivatives and preparing method and uses thereof
CN103965175B (en) * 2013-02-05 2017-12-22 齐鲁制药有限公司 4- (substituted phenylamino) quinazoline compounds, their preparation method and application
WO2017141271A1 (en) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical composition of afatinib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
DE69536015D1 (en) 1995-03-30 2009-12-10 Pfizer Prod Inc quinazolinones derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1997002266A1 (en) 1995-07-06 1997-01-23 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EP0799619A3 (en) 1996-03-27 1997-11-12 Pfizer Inc. Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and treatment of benign prostatic hyperplasia
CN1923818A (en) * 1996-04-12 2007-03-07 沃尼尔·朗伯公司 Irreversible inhibitors of tyrosine kinases
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO1998043960A1 (en) * 1997-04-03 1998-10-08 American Cyanamid Company Substituted 3-cyano quinolines
US6127374A (en) * 1997-07-29 2000-10-03 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
WO1999006396A1 (en) 1997-07-29 1999-02-11 Warner-Lambert Company Irreversible bicyclic inhibitors of tyrosine kinases
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
JP4988984B2 (en) * 1997-08-01 2012-08-01 ワイス・ホールディングズ・コーポレイション Their use as substituted quinazoline derivatives and tyrosine kinase inhibitors
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6262088B1 (en) 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
EP2298746A1 (en) 1999-02-27 2011-03-23 Boehringer Ingelheim Pharma GmbH & Co. KG 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
DE19911509A1 (en) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for their preparation
DE19911366A1 (en) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
US20060063752A1 (en) * 2000-03-14 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
ES2552813T3 (en) * 1999-06-21 2015-12-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, medicaments containing these compounds, their use and process for their preparation
EP1274692B1 (en) * 2000-04-07 2006-08-02 AstraZeneca AB Quinazoline compounds
EP1280798B1 (en) 2000-04-08 2007-01-03 Boehringer Ingelheim Pharma GmbH &amp; Co.KG Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them
US6627634B2 (en) * 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US7084136B2 (en) * 2000-06-02 2006-08-01 Shionogi & Co., Ltd. Drug composition antagonistic to both PGD2/TXA2 receptors
US6656946B2 (en) * 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042060A1 (en) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for their preparation
US6617329B2 (en) * 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
DE10042062A1 (en) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for their Hertel Lung
DE10042058A1 (en) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for their preparation
US6740651B2 (en) * 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6403580B1 (en) * 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE10042059A1 (en) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for their preparation
DE10042064A1 (en) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma , Pharmaceuticals containing these compounds, quinazolines, their use and processes for their preparation
WO2002041882A3 (en) 2000-11-22 2002-09-06 Guido Bold Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10063435A1 (en) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate medicaments containing these compounds, their use and processes for their preparation
DE10204462A1 (en) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
DK1487806T3 (en) * 2002-03-28 2010-09-20 Astrazeneca Ab 4-anilino-quinazoline derivatives as antiproliferative agents
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1492536B1 (en) 2002-03-30 2012-05-09 Boehringer Ingelheim Pharma GmbH & Co.KG 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
DE10217689A1 (en) 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US20040044014A1 (en) * 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10221018A1 (en) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Use of inhibitors of EGFR-mediated signal transduction in the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
US20030225079A1 (en) * 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
WO2004069791A3 (en) * 2003-02-05 2004-12-16 Hubert Gangolf Klemens Barth Preparation of substituted quinazolines
DE10307165A1 (en) 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US7223749B2 (en) * 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10326186A1 (en) * 2003-06-06 2004-12-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for their preparation
DE10345875A1 (en) 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclic heterocycles medicaments containing these compounds, their Vewendung and processes for their preparation
US7456189B2 (en) * 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (en) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma A process for preparing Aminocrotonylverbindungen
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
JP5688877B2 (en) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Treatment for a quinazoline derivative of the cancer disease
US20090306101A1 (en) * 2005-11-11 2009-12-10 Flavio Solca Combination treatment of cancer comprising egfr/her2 inhibitors
EP1981863B1 (en) 2006-01-26 2012-10-10 Boehringer Ingelheim International GmbH Process for preparing aminocrotonylamino-substituted quinazoline derivatives
US8877764B2 (en) * 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
ES2588031T3 (en) 2008-06-06 2016-10-28 Boehringer Ingelheim International Gmbh solid pharmaceutical formulations comprising BIBW 2992
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
EP2451445A2 (en) 2009-07-06 2012-05-16 Boehringer Ingelheim International GmbH Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US20130012465A1 (en) 2009-12-07 2013-01-10 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines

Cited By (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722694B2 (en) 1999-06-21 2014-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20100069414A1 (en) * 1999-06-21 2010-03-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20110046168A1 (en) * 2000-12-20 2011-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methods of treating diseases using quinazoline derivatives and pharmaceutical compositions containing them
USRE43431E1 (en) 2000-12-20 2012-05-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US8586608B2 (en) 2000-12-20 2013-11-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US20100010023A1 (en) * 2000-12-20 2010-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US20060247226A1 (en) * 2001-02-24 2006-11-02 Frank Himmelsbach Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20080103161A1 (en) * 2002-04-19 2008-05-01 Frank Himmelsbach Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US7863281B2 (en) 2002-04-19 2011-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US20100144639A1 (en) * 2002-05-11 2010-06-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph) / prostatic hypertrophy
US8431585B2 (en) 2002-05-11 2013-04-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
US9321791B2 (en) 2002-08-21 2016-04-26 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20080255159A1 (en) * 2002-08-21 2008-10-16 Boehringer Ingelheim Pharma Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9556175B2 (en) 2002-08-21 2017-01-31 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
US8119648B2 (en) 2002-08-21 2012-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8664232B2 (en) 2002-08-21 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8178541B2 (en) 2002-08-21 2012-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9108964B2 (en) 2002-08-21 2015-08-18 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7838529B2 (en) 2002-08-22 2010-11-23 Boehringer Ingelheim International Gmbh Xanthine derivates, their preparation and their use in pharmaceutical compositions
US20040166125A1 (en) * 2002-08-22 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US20090131432A1 (en) * 2002-08-22 2009-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivates, their preparation and their use in pharmaceutical compositions
US7696212B2 (en) 2002-11-08 2010-04-13 Boehringer Ingelheim Pharma Gmbh And Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040138214A1 (en) * 2002-11-08 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20100144703A1 (en) * 2002-11-08 2010-06-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7560450B2 (en) * 2002-11-21 2009-07-14 Boehringer Ingelheim Pharma Gmbh & Co., Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040138215A1 (en) * 2002-11-21 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7846936B2 (en) 2003-04-29 2010-12-07 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20110039863A1 (en) * 2003-04-29 2011-02-17 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
US20110136826A1 (en) * 2003-04-29 2011-06-09 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
US20080254040A1 (en) * 2003-04-29 2008-10-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20110171289A1 (en) * 2003-04-29 2011-07-14 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
US20090258856A1 (en) * 2003-06-18 2009-10-15 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US8034941B2 (en) 2003-06-18 2011-10-11 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US8426586B2 (en) 2003-10-17 2013-04-23 Boehringer Ingelheim International Gmbh Process for preparing amino crotonyl compounds
US20070027170A1 (en) * 2003-10-17 2007-02-01 Rainer Soyka Process for preparing amino crotonyl compounds
US7550455B2 (en) 2003-11-27 2009-06-23 Boehringer Ingelheim International Gmbh 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition
US8697868B2 (en) 2004-02-18 2014-04-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20050234108A1 (en) * 2004-02-18 2005-10-20 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20090137801A1 (en) * 2004-02-18 2009-05-28 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7645763B2 (en) 2004-02-23 2010-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition
US20050187227A1 (en) * 2004-02-23 2005-08-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition
US20090088569A1 (en) * 2004-04-10 2009-04-02 Matthias Eckhardt 2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation, and their use as pharmaceutical compositions
US20050261352A1 (en) * 2004-05-10 2005-11-24 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US7667035B2 (en) 2004-05-10 2010-02-23 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US20080312243A1 (en) * 2004-06-24 2008-12-18 Matthias Eckhardt Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US20060004074A1 (en) * 2004-06-24 2006-01-05 Boehringer Ingelheim International Gmbh New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US7906539B2 (en) 2004-06-24 2011-03-15 Boehringer Ingelheim International Gmbh Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US7470716B2 (en) 2004-06-24 2008-12-30 Boehringer Ingelheim International Gmbh Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US7495003B2 (en) 2004-09-11 2009-02-24 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060058323A1 (en) * 2004-09-11 2006-03-16 Boehringer Ingelheim International Gmbh New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495002B2 (en) 2004-09-14 2009-02-24 Boehringer Ingelheim International Gmbh 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060079541A1 (en) * 2004-09-14 2006-04-13 Boehringer Ingelheim International Gmbh 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20090192314A1 (en) * 2004-11-05 2009-07-30 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
US7820815B2 (en) 2004-11-05 2010-10-26 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US20060142310A1 (en) * 2004-11-05 2006-06-29 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US8883805B2 (en) 2004-11-05 2014-11-11 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9499546B2 (en) 2004-11-05 2016-11-22 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9751855B2 (en) 2004-11-05 2017-09-05 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US8541450B2 (en) 2004-11-05 2013-09-24 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
US8106060B2 (en) 2005-07-30 2012-01-31 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US20070027168A1 (en) * 2005-07-30 2007-02-01 Waldemar Pfrengle 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8637530B2 (en) 2005-07-30 2014-01-28 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US9539258B2 (en) 2005-11-11 2017-01-10 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US8404697B2 (en) 2005-11-11 2013-03-26 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US9089571B2 (en) 2005-11-11 2015-07-28 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US20090306044A1 (en) * 2005-11-11 2009-12-10 Flavio Solca Quinazoline derivatives for the treatment of cancer diseases
US20090306101A1 (en) * 2005-11-11 2009-12-10 Flavio Solca Combination treatment of cancer comprising egfr/her2 inhibitors
US8188274B2 (en) 2006-01-26 2012-05-29 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
US20110207929A1 (en) * 2006-01-26 2011-08-25 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
US20090306378A1 (en) * 2006-01-26 2009-12-10 Juergen Schroeder Process for preparing aminocrotonylamino-substituted quinazoline derivatives
US8067593B2 (en) 2006-01-26 2011-11-29 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
US7960546B2 (en) 2006-01-26 2011-06-14 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
US20110207932A1 (en) * 2006-01-26 2011-08-25 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
US8673927B2 (en) 2006-05-04 2014-03-18 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US8232281B2 (en) 2006-05-04 2012-07-31 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US9493462B2 (en) 2006-05-04 2016-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US20070259900A1 (en) * 2006-05-04 2007-11-08 Peter Sieger Polymorphs
US20080107731A1 (en) * 2006-05-04 2008-05-08 Anja Kohlrausch Dpp iv inhibitor formulations
US20070281940A1 (en) * 2006-05-04 2007-12-06 Klaus Dugi Uses of dpp-iv inhibitors
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US9173859B2 (en) 2006-05-04 2015-11-03 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US9815837B2 (en) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh Polymorphs
US8071583B2 (en) 2006-08-08 2011-12-06 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
US20090318480A1 (en) * 2006-09-18 2009-12-24 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
US8877764B2 (en) 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9415016B2 (en) 2008-04-03 2016-08-16 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US8545884B2 (en) 2008-06-06 2013-10-01 Boehringer Ingelheim International Gmbh Solid pharmaceutical formulations comprising BIBW 2992
US20110142929A1 (en) * 2008-06-06 2011-06-16 Boehringer Ingelheim International Gmbh Solid pharmaceutical formulations comprising bibw 2992
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US9212183B2 (en) 2008-12-23 2015-12-15 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9603851B2 (en) 2010-05-05 2017-03-28 Boehringer Ingelheim International Gmbh Combination therapy
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
US9199998B2 (en) 2011-07-15 2015-12-01 Boehringer Ingelheim Internatioal Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US9556191B2 (en) 2013-04-28 2017-01-31 Sunshine Lake Pharma Co., Ltd. Aminoquinazoline derivatives and their salts and methods of use thereof
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor

Also Published As

Publication number Publication date Type
JP2003502410A (en) 2003-01-21 application
EP1731511B1 (en) 2015-08-12 grant
JP3686610B2 (en) 2005-08-24 grant
US20120329778A1 (en) 2012-12-27 application
EP1731511A1 (en) 2006-12-13 application
CA2375259C (en) 2009-04-28 grant
WO2000078735A1 (en) 2000-12-28 application
CN1356990A (en) 2002-07-03 application
EP1194418A1 (en) 2002-04-10 application
CA2375259A1 (en) 2000-12-28 application
CN1166645C (en) 2004-09-15 grant
DK1731511T3 (en) 2015-10-26 grant
ES2552813T3 (en) 2015-12-02 grant
US20100069414A1 (en) 2010-03-18 application
US20020169180A1 (en) 2002-11-14 application
US8722694B2 (en) 2014-05-13 grant
US7220750B2 (en) 2007-05-22 grant

Similar Documents

Publication Publication Date Title
US6479488B1 (en) Tetrahydroquinoline derivatives as EAA antagonists
US6265411B1 (en) Oxindole derivatives
US6297258B1 (en) Substituted 3-cyanoquinolines
US6288082B1 (en) Substituted 3-cyanoquinolines
US20040242603A1 (en) Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same
US7456189B2 (en) Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US7579473B2 (en) c-Met modulators and methods of use
WO1997034876A1 (en) Cinnoline derivatives and use as medicine
WO2008150118A2 (en) Novel amide derivative for inhibiting the growth of cancer cells
WO2000018761A1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
WO1996029331A1 (en) Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
EP1369418A1 (en) Quinazoline derivatives
WO2003045395A1 (en) Quinazoline derivatives for the treatment of t cell mediated diseases
US6924285B2 (en) Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
WO2002030924A1 (en) Quinazoline derivatives with anti-tumour activity
WO1997032881A1 (en) 4-amino pyrimidine derivates, medicaments containing these compounds, their use and process for their production
WO2002034744A1 (en) Quinazoline derivatives
WO2000018740A1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US7196091B2 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20040029898A1 (en) Substituted quinolines as antitumor agents
US6656946B2 (en) Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US7019012B2 (en) Quinazoline derivatives and pharmaceutical compositions containing them
WO2003082290A1 (en) 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
WO2002085895A1 (en) Quinazoline derivatives
US6403580B1 (en) Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them